Drug, bio-affecting and body treating compositions inventions 04/07

20070092440 - Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial: The present invention relates to a method for the improved treatment of a cancerous disease in a patient and/or for the palliation of pain associated with cancer diseases, comprising the administration of a tubulin interacting compound in combination with a bone-localising radiopharmaceutical to said patient in an effective amount that... Agent: Millen, White, Zelano & Branigan, P.C.

20070092442 - F-18-fluorinated phosphonium cation imaging agents and methods of synthesis: The present disclosure provides mitochondrial imaging probes, particularly imaging probes capable of imaging changes in mitochondrial membrane potential and conditions associated with mitochondrial dysfunction.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20070092441 - Fluoridation method: A method for the fluoridation of an iodonium salt with a fluoride ion source which can be carried out in an aqueous reaction solvent.... Agent: Ge Healthcare, Inc.

20070092443 - Antibodies that recognize hyperproliferative cells and methods of making and using same: The invention relates to antibodies that bind to antigens, such as antigens associated with hyperproliferating cells, and methods of treating hyperproliferative disorders. The invention antibodies are useful for treating hyperproliferative disorders, such as neoplasia.... Agent: Wilson Sonsini Goodrich & Rosati

20070092444 - Inhibition of inward sodium currents in cancer: Described is a constitutive inward Na+ currents found in a variety of human cancers. The constitutive inward Na+ current plays a role in increased cellular proliferation, cellular migration and volume regulation. The inward current is mediated, at least in part, by AISC-containing Na+ channels. In addition, an inhibitor of the... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20070092445 - Assessing ovarian reserve: Methods for assessing the ovarian reserve of a female subject may include (a) testing the concentration of follicle stimulating hormone (FSH) in urine samples obtained from the subject, the samples being obtained on at least two different days during a first menstrual cycle in the subject; (b) testing the concentration... Agent: Foley Hoag, LLP Patent Group, (w/isa)

20070092447 - Contrast agent for combined modality imaging and methods and systems thereof: A combined modality imaging system includes a first imaging device of a first modality and a second imaging device of a second modality that is different from the first modality is provided. The first and the second imaging devices are both adapted to interact with a contrast agent. The contrast... Agent: General Electric Company Global Research

20070092446 - Patient selection method for assisting weight loss: A method is provided for identifying a patient as being suitable for implantation of a weight-loss assist device. The method includes identifying the patient as being generally suitable for the implantation and subsequently, measuring a value associated with the patient. Responsively to determining that the value is beyond a threshold... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20070092448 - Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same: The present invention provides methods which use induction phenomenon of production of interleukin 18 (IL-18) from keratinocyte (KC), and their usages. The methods are preferably applicable for understanding of pathogenic mechanisms of atopic dermatitis (AD) and AD-like symptoms, and for development of therapeutic drugs for AD and AD-like symptoms. For... Agent: Edwards & Angell, LLP

20070092449 - Methods for direct visualization of active synapses: A method for visualizing an active synapse wherein said method comprises: (a) exposing cells forming the active synapse to a biomarker comprising at least fragment C of tetanus toxin and a reporter protein; and (b) visualizing the biomarker; wherein the accumulation of the biomarker into dendritic spines of the cells... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070092450 - Tissue-specific exogenous optical agents: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume... Agent: Wood, Herron & Evans, LLP

20070092451 - Time indicating containers for dental compositions: A system for storing a dental composition having a given shelf-life. The storage system includes a container (e.g., a syringe) and activatable time sensitive marking means disposed on or within the container. Upon activation of the time sensitive marking means, the system begins to indicate time lapsed since activation. The... Agent: Rick D. Nydegger Workman Nydegger

20070092452 - Methods for fabrication, uses, compositions of inhalable spherical particles: Inhalable spherical particles that contain an active agent having unexpectedly good bioavailability when compared to the expected bioavailability are disclosed. Inhalable spherical particles, particles of the agent that contain an amount of a cation such as zinc provide for further improvement in bioavailability.... Agent: Baxter Healthcare Corporation

20070092453 - Novel crystalline forms of tiotropium bromide: The invention relates to a new crystalline forms of tiotropium bromide, processes for preparing them and their use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070092455 - Aqueous slurries useful for cleaning teeth and methods related thereto: Novel aqueous slurries capable of removing calculus, plaque or stains, adherent to tooth surfaces of a warm-blooded animal, when used in methods that are self-practicable by an individual human or practicable by an individual human on another warm-blooded animal, combine finely-divided charcoal; water; and alcohol, ammonia or hydrogen peroxide to... Agent: Seed Intellectual Property Law Group PLLC

20070092454 - Oral composition containing morin: The present invention relates to an oral composition useful to reduce inflammatory processes. More specifically, the invention relates to a composition consisting essentially of an anti-oxidative effective amount of morin and a water-humectant phase, and to a composition comprising an anti-oxidative effective amount of morin, one or more anti-bacterial agents... Agent: Colgate-palmolive Company

20070092456 - Protectant of periodontal membranes: e

20070092457 - Compositions comprising polymeric emulsifiers and methods of using the same: Provided are oil-in-water sunscreen compositions comprising inorganic sunscreens and polymeric emulsifiers that are substantially free of hydrophobic modification, and methods of using the same.... Agent: Philip S. Johnson Johnson & Johnson

20070092458 - Compositions comprising polymeric emulsifiers and methods of using the same: Provided are oil-in-water sunscreen compositions comprising inorganic sunscreens and polymeric emulsifiers that are substantially free of hydrophobic modification, and methods of using the same.... Agent: Philip S. Johnson Johnson & Johnson

20070092459 - Cosmetic preparation with 1,2-alkanediol and triazines: A cosmetic preparation which comprises one or more 1,2-alkanediols and one or more UV light-protection filters from the group of triazine derivatives. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.... Agent: Greenblum & Bernstein, P.L.C

20070092460 - Silylated compounds as precursors for self-tanning compositions: The use of silylated compounds as precursors of skin self-tanning substances in self-tanning compositions is described.... Agent: Ciba Specialty Chemicals Corporation Patent Department

20070092461 - Novel hydroxy acid complexes for antiaging and skin renovation: This invention relates to certain divalent and polyvalent d-orbital metals of first transition series of the Periodic Table of Elements, from Group IV to Group VI, and including Molybdenum, complexed concurrently with an amino acid, or an equivalent of an amino acid, and a hydroxy acid in a novel spirocyclic... Agent: Shyam K. Gupta Bioderm Research

20070092462 - Cosmetic compositions: A cosmetic composition comprising in a preblend; or in a the resting state prior to application to a keratinous surface, at least one peptide, at least one collagen containing compound, at least one penetration enhancer, at least one mucopolysaccharide, and at least one proteoglycan; wherein said ingredients are operable to... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070092463 - Semi (soft)-solid antiperspirant compositions: Stable semi-solid anhydrous antiperspirant compositions comprising an antiperspirant powder, a volatile silicone and non-volatile materials, a primary gellant material comprising Glyceryl monostearate, secondary gellants, oil absorbents, and coupling agents. The resultant products exhibit minimal syneresis with any dispensing package and exhibiting dry feeling when applied to skin.... Agent: The Halvorson Law Firm

20070092464 - Betadine neutralizer: A new preparation for the removal of iodine stains in clinical or home environments is disclosed as an aqueous solution of a metabisulfite in the preferred range of 0.01 to 0.04 percent by weight, metabisulfite to water. The preferred metabisulfite for this purpose is sodium metabisulfite. In one embodiment of... Agent: Christopher D. Harrington Suite 350

20070092466 - Compositions and methods for treating hair loss using c16-c20 aromatic tetrahydro prostaglandins: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.... Agent: Michael Best & Friedrich, LLP

20070092465 - Methods for enhancing the morphology, tone, texture and/or appearance of skin or hair using a meadowlactone: The present invention provides inexpensive, safe and reliable methods for improving the morphology, tone, texture and/or appearance of the skin and/or hair of a mammal, preferably without using one or more surfactants (or other chemicals) that can strip away, or otherwise remove, one or more protective lipids from the skin... Agent: Keith D. Parr Lord, Bissell & Brook LLP

20070092467 - Oxyacetamide compounds useful for stimulating or inducing the growth and/or retarding the loss of keratin fibers: e

20070092470 - Liquid, peg-free, cold-processable oil-in-water emulsifiers: The invention provides liquid, cold-processable oil-in-water emulsifier systems comprising a liquid, PEG-free emulsifier base consisting of A) one or more polyol partial esters, Ba) one or more acid partial esters carrying neutralizable acid functions, or Bb) one or more acid partial esters carrying at least partially neutralized acid functions, and... Agent: Leopold Presser Scully, Scott, Murphy & Presser

20070092469 - Topically applied glucosamine sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while phosphatidylcholine is re: A topical skin rejuvenation preparation to relieve wrinkles, increase the skin's natural production of hyaluronic acid, reverse the lack of suppleness, hydrate from within, erase spider veins, reduce varicose veins, lighten aging dark blotches (“liver spots”/Lentigos, Senile Lentigines), decrease acne, and reduce under eye puffiness includes Glucosamine (2-amino-2-deoxy-alpha-D-glucose), a hexosamine... Agent: Eric Jacobs

20070092471 - Composition for the oxidative treatment of hair or skin fixative compostion and method for permanent deformation of hair: Cosmetic composition for the oxidative treatment of hair or skin, prepared by mixing of at least two components, in which dehydroascorbic acid or a dehydroascorbic acid salt or a dehydroascorbic acid derivative is generated from ascorbic acid, ascorbic acid derivative and ascorbic acid salt prior to application by an enzyme... Agent: Striker, Striker, & Stenby

20070092472 - Skin care composition for accelerated production of collagen proteins and method of fabricating same: A liquid solution for topical application to the skin of an animal consists of solutes and a solvent, where the solutes include ascorbate, tropocollagen, copper, and zinc glutonate.... Agent: Marger Johnson & Mccollom, P.C.

20070092473 - Cosmetic composition containing a statistical polymer with a linear main chain of ethylenic nature: l

20070092474 - Carnitine salt, preliposome which contains it and dermocosmetic formula for topical use based upon said carnitine salt: The carnitine salt consisting of carnitine hydroxy citrate of formula (I) of natural origin for treating skin blemishes linked to physiological disorders ascribable to cellulite and anomalous adiposity connected to this. With respect to conventional solutions, the new carnitine salt of the invention proves to be particularly efficient and, above... Agent: The Firm Of Karl F Ross

20070092476 - Compounds and use to reduce the formation of malodour: Malodour formation reducing compounds alpha-N-(3-Methyl-5-phenylpentanoxycarbonyl)-L-glutamine, alpha-N-(2-Methyl-5-phenylpentanoxycarbonyl)-L-glutamine, and alpha-N-(2,4-Dimethyl-4-phenylbutanoxycarbonyl)-L-glutamine, and their salts, compositions comprising such compounds, including cosmetic products, personal care products, and deodorant products, and methods forming such products and their use. The compounds are useful to reduce the formation of human malodour resulting from bacterial degradation of compounds naturally... Agent: Curatolo Sidoti Co., Lpa

20070092475 - Methods for enhancing the morphology, tone, texture and/or appearance of skin using a meadowestolide: The present invention provides inexpensive, safe and reliable methods for improving the morphology, tone, texture and/or appearance of the skin of a mammal, preferably without using one or more surfactants (or other chemicals) that can strip away, or otherwise remove, one or more protective lipids of the skin. These methods... Agent: Keith D. Parr Lord, Bissell & Brook LLP

20070092477 - Cleaning compositions: Improved treatment blocks useful in the treatment of lavatory appliances, particularly toilets are provided. The improved treatment blocks are solid block compositions which comprise at least one detersive surfactant, a diester constituent, and one or more further optional constituents, including bleach constituents. The improved treatment blocks provide improved processing and... Agent: Norris, Mclaughlin & Marcus

20070092478 - Emulsion comprising 1,2-alkanediols and polar oil components: An emulsion comprising (a) more than about 40% by weight, based on the total weight of the lipid phase of the emulsion, of one or more polar and/or moderately polar lipids which exhibit an interfacial tension towards water of less than about 30 mN/m and (b) one or more 1,2-alkanediols... Agent: Greenblum & Bernstein, P.L.C

20070092468 - Cosmetic compositions: A cosmetic composition having improved transfer resistance comprising: a) from about 0.1-60% by weight of trimethylated silica, b) from about 0.1-60% by weight of a volatile solvent having a viscosity of 0.5 to 100 centipoise at 25° C., c) 0.1-60% by weight of a nonvolatile oil having a viscosity of... Agent: Julie Blackburn, Esq. Revlon Consumer Products Corporation, Law Dept.

20070092479 - Odor mitigation compositions, devices, and methods: Methods, devices, and corresponding compositions for generally simultaneously camouflaging and suppressing odors by applying at least one odor absorbing agent, optionally a plurality of differently colored odor absorbing agents, directly to a user and/or to garments and/or accessories used in hunting and/or observing and/or photographing wild animals. The odor absorbing... Agent: Wilhelm Law Service, S.c.

20070092480 - Inducible release vehicles: This invention relates to inducible release vehicle comprised of crosslinked carbohydrates or proteins and an active ingredient. The release is induced by an external stimulus, e.g. an enzyme such as amylase. Such a vehicle can particularly be used in applications for preventing microbial decay or combating microbial infections. Other uses... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20070092482 - Conjugates of a g-csf moiety and a polymer: Conjugates of a G-CSF moiety and one or more nonpeptidic water-soluble polymers are provided. Typically, the nonpeptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions comprising conjugates to a patient.... Agent: Nektar Therapeutics

20070092483 - Surgical adhesive compostion and process for enhanced tissue closure and healing: A surgical tissue adhesive composition contains at least one 1,1-disubstituted electron-deficient olefin macromer. The adhesive composition of the invention has improved biocompatibility as well as controlled biodegradation characteristics and bioactivity. Adhesive co-monomer compositions contain at least one macromer with a pendant oligomer, polymer, or peptide chain as an acrylic ester... Agent: Dergosits & Noah LLP

20070092481 - Thickened cyanoacrylate compositions: The present invention relates to thickened cyanoacrylate compositions, such as those in gel or non-flowable forms. More particularly, the present invention relates to non-flowable cyanoacrylate compositions which can be packaged in a convenient pocket-sized applicator dispenser for use in spreading the cyanoacrylate compositions onto substrates.... Agent: Loctite Corporation

20070092485 - Cytokine zalpha11 ligand: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20070092486 - Glycolated and glycosylated poultry derived therapeutic proteins: Compositions containing a glycosylated therapeutic amino acid sequence obtained from a transgenic avian wherein the therapeutic amino acid sequence is a glycoprotein and includes a covalently bonded glycol polymer.... Agent: Avigenics, Inc.

20070092484 - Mcp-1 splice variants and methods of using same: Novel MCP-1 splice variant polypeptides and polynucleotides encoding same are provided. Also provided are pharmaceutical compositions comprising the splice variant polypeptides and polynucleotides, vectors and host cells comprising same. The compositions of the present invention are useful to treat various MCP-1 related disorders as well as for diagnosing, determining predisposition... Agent: Staas & Halsey LLP

20070092488 - Methods of treating idiopathic pulmonary fibrosis: The present invention provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF; and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-γ to an individual with IPF.... Agent: Foley & Lardner LLP

20070092487 - Stabilized liquid protein formulations in pharmaceutical containers: A container comprising a closure means coated by an inert fluorinated material and containing a liquid pharmaceutical composition. In particular, the container comprises a closure means coated by TEFLON and contains a HSA-free Interferon-β formulation having the following composition: 30 to 100 μg/ml of interferon-β, an isotonicity agent, 0.1 to... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070092490 - High efficiency sin vector: The present application discloses viral vector that includes the following elements: (1) a promoter in U3 region of MSV 5′LTR; (2) repeating unit of MSV 5′LTR; (3) U5 region of MSV 5′LTR; (4) packaging signal; (5) a promoter; (6) internal ribosome entry site (IRES); (7) defective MLV 3′ LTR; (8)... Agent: Jhk Law

20070092489 - Use of receptor sequences for immobilizing gene vectors on surfaces: The present invention relates to compositions and methods of immobilizing a viral vector to an implantable medical device, for example a vascular stent. Specifically, a composition for delivery of a therapeutic agent is provided which includes: a gene transfer vector, a surface and a modified protein, wherein the gene transfer... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070092499 - Method for changing genetic properties of eukaryotic organism: The invention provides a method for changing the genetic properties of an eukaryotic organism by suppression of expression of a target gene. Proposed method can be used in gene-therapy in medicine, agriculture, or industrial biotechnology. Genetic properties of an eukaryotic organism are changed by gene-specific silencing of a selected gene... Agent: Buchanan, Ingersoll & Rooney PC

20070092500 - Methods and pharmaceutical compositions for differentially altering gene expression to provide neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma and metal poisoning: Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and/or stabilizing hypoxia-inducible factor-1α (HIF-1α).... Agent: Altera Law Group, LLC

20070092498 - Methods of diagnosing, prognosing and treating breast cancer: The protein pRb2/p130 represses expression of the ER-α gene. Blocking pRb2/p130 expression or altering ER-α gene methylation to alter pRb2/p130 complex binding allows transcriptional activity of the ER-α gene to be restored. Detecting and regulating the methylation state of the ER-α gene, optionally together with detecting and regulating pRb2/p130 multimolecular... Agent: Ip Group Of Dla Piper US LLP

20070092491 - Novel strain of bacillus as a bioinoculant: The present invention relates to the selection and development of superior strain of Bacillus spp for improving plant growth and health by inhibiting pathogenic fungi... Agent: Sughrue Mion, PLLC

20070092494 - Composition for wound healing using lyophilized skin or skin-derived collagen: A wound healing composition for repairing a wound in a human or animal subject, comprising a first skin tissue material and a carrier comprising collagen derived from a second skin tissue material. Methods of making the wound healing composition and methods of augmenting a wound site with the composition are... Agent: Harness, Dickey & Pierce, P.L.C

20070092497 - Cytotherapeutics, cytotherapeutic units and methods for treatments using them: The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are... Agent: Jones Day

20070092493 - Living cell sheet: A novel method, using a thermoreversible MC/PBS/Collagen hydrogel coated on the TCPS dish, for harvesting a living cell sheet with ECM. The coated hydrogel system is reusable and can be used for culturing a multi-layer cell sheet. The obtained living cell sheets may be used for tissue reconstructions.... Agent: Hosheng Tu

20070092496 - Method of delivering cells to the skin: The present invention is a method of forming egressing hair shafts comprising making a wound in the skin and placing hair follicle progenitor cells on the wound, wherein an egressing hair shaft is formed from the hair follicle progenitor cells. The present invention is also a method of forming new... Agent: Michael Best & Friedrich, LLP

20070092495 - Methods for regulating differentiation of neural cells and uses thereof: The present invention provides methods for promoting or suppressing differentiation of neural stem/progenitor cells, for producing differentiated neural cells, and for isolating/purifying differentiated neural cells. Also provided are differentiated neural cells, cell populations and transgenic animals comprising same, and uses of same. The present invention further provides methods for treating... Agent: Baker & Botts L.L.P.

20070092492 - Three-dimentional tissue structure: The present invention provides a prosthetic tissue or sheet capable of withstanding implantation operations, which can be used in actual operation and can be produced by culture. The present invention also provides a novel therapy which can substitute for cell therapy. Particularly, the present invention provides a method for producing... Agent: Snell & Wilmer L.L.P. (main)

20070092501 - Compositions and methods relating to reduction of symptoms of autism: Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin... Agent: Graybeal, Jackson, Haley LLP

20070092502 - Method of treating glaucoma: The present invention provides a method of treating glaucoma or preventing glaucoma in a person at risk of developing glaucoma, by applying to the eye of said person, an effective amount of an antibacterial agent having activity against the Heliocobacter Pylori bacteria to thereby eradicate, inhibit and/or control said bacteria.... Agent: Allergan, Inc.

20070092503 - Human alkaline sphingomyelinase and use thereof: An isolated human alkaline sphingomyelinase (Alk-Smase) or a variant thereof is capable of hydrolysing sphingomyelin. Methods are provided for isolating human Alk-Smase and for preparing human recombinant Alk-Smase. Further methods are provided for the use of the enzyme for the treatment of colon cancer.... Agent: Albihns Stockholm Ab

20070092507 - Anti-fcrn antibodies for treatment of auto/allo immune conditions: Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or antigen binding fragments thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as... Agent: Hodgson Russ LLP

20070092505 - Production of humanized antibodies in transgenic animals: This invention relates to humanized antibodies and antibody preparations produced from transgenic non-human animals. The non-human animals are genetically engineered to contain one or more humanized immunoglobulin loci which are capable of undergoing gene rearrangement and gene conversion in the transgenic non-human animals to produce diversified humanized immunoglobulins. The present... Agent: Heller Ehrman LLP

20070092504 - Use of agents that modulate the interaction between pd-1 and its ligands in the downmodulation of immune responses: Disclosed are methods for downmodulating an immune response comprising contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1) to thereby modulate the immune response.... Agent: Lahive & Cockfield, LLP

20070092506 - Use of rapamycin and agents that inhibit b7 activity in immunomodulation: The invention provides methods for downmodulating an immune response comprising contacting immune cells from a subject with at least one agent that binds to at least one B7 molecule in combination with a Rapamycin compound.... Agent: Foley Hoag, LLP Patent Group, (w/wys)

20070092508 - Detoxification depot for alzheimer's disease: The invention is directed to a device that is placed inside an Alzheimer's disease (AD) patient for the purpose of extracting and accumulating neurotoxic beta-amyloid peptides (nt-bAP) from body fluids. AD is the consequence of a process in which nt-bAP aggregates to form fibrils and plaques which can cause nerve... Agent: Mccormick, Paulding & Huber LLP

20070092509 - Method for ex-vivo separation of apoptotic chromatin fragments from blood or plasma for prevention and treatment of diverse human diseases: A method of prevention/treatment of pathological consequences of DNA damage triggered by incorporation of circulating apoptotic chromatin fragments into healthy cells of individuals/patients in need therefore, said method comprising ex vivo or extra corporeal treatment of blood/plasma for removal of circulating chromatin fragments released from apoptotic cells which apoptotic chromatin... Agent: Merchant & Gould PC

20070092510 - Cns chloride modulation and uses thereof: Methods and products for the attenuation or treatment of pain and the reduction of nociception are described. The methods and products are based on the modulation of CNS intracellular chloride levels. The methods and products may also relate to modulation of the activity and/or expression of a chloride transporter, such... Agent: Ladas & Parry LLP

20070092513 - Erbb4 antagonists: The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing... Agent: Heller Ehrman LLP

20070092511 - Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells: The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4+ T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified extracellular domains of ligands. The invention also provides humanized and human antibodies to the ligand. The invention further provides methods of using the... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070092514 - Novel secreted immunomodulatory proteins and uses thereof: The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding... Agent: Millennium Pharmaceuticals, Inc.

20070092512 - Preventing bacterial or viral infectivity and composition containing infection preventing additive: A nitric oxide synthesis inhibitor or nitric oxide scavenger is administered to prevent development of infection, to prevent development of a cancer where overstimulation of a receptor contributes to the cancer development, and to prevent loss of beta agonist responsivity and as a treatment in combination with a receptor blocker.... Agent: Bacon & Thomas, PLLC

20070092516 - Antibody preparation: An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants... Agent: Nixon & Vanderhye, PC

20070092515 - Methods of treating chronic pain using compositions that specifically bind cd11d (alpha-d) integrin: Methods to treat secondary injury resulting from spinal cord injury using polypeptide compositions that specifically bind to CD11d are disclosed.... Agent: Marshall, Gerstein & Borun LLP

20070092518 - Anti-tnfalpha antibodies and methods of use: Novel TNFα antibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to treat TNFα-related diseases are also disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20070092517 - Truncated memapsin 2 compositions and treatments: The present invention provides novel methods of reducing memapsin 2 β-secretase activity in a subject, decreasing levels of β-amyloid peptide in the brain of a subject, treating Alzheimer's disease and/or reducing the size and/or number of β-amyloid plaques in the brain of a subject. The methods may include the step... Agent: Townsend And Townsend And Crew, LLP

20070092521 - Antibody-based therapeutics with enhanced adcc activity: Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070092520 - Humanized anti-cmet antagonists: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.... Agent: Genentech, Inc.

20070092522 - Method and composition for reconforming multi-epitopic antigens to initiate an immune response: The invention concerns methods and compositions for initiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070092519 - Method for diagnosing chronic myeloid leukemia: Objective methods for detecting and diagnosing Chronic myeloid leukemia (CML) are described herein. In one embodiment, the diagnostic method involves the determining a expression level of CML-associated gene that discriminate between CML and normal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment... Agent: Townsend And Townsend And Crew, LLP

20070092523 - Combination therapy of respiratory diseases using antibodies: Therapeutically effective anti-microbial compositions, useful especially against respiratory diseases caused or mediated by viruses, bacteria, and other respiratory parasites are disclosed, wherein said compositions comprise at least one neutralizing antibody, including high affinity antibodies, and an additional anti-infectious agent, such as an antiviral agent, for example, ribavirin, amantadine, rimantadine, or... Agent: Johnathan Klein-evans

20070092524 - Method for the treatment and prophylaxis of avian influenza infection: This invention relates to methods and compositions for treatment and prevention of Avian Influenza. Specifically, the invention relates to the use of immunoglobulins obtained from a subject immune to Avian Influenza in the preparation and use of pharmaceutical preparations for the treatment of Avian Influenza.... Agent: Pearl Cohen Zedek Latzer, LLP

20070092525 - Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates... Agent: Fulbright & Jaworski L.L.P.

20070092526 - Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use: Improved polynucleotide vaccine adjuvants and related polynucleotide vaccine formulations are disclosed which are useful in prophylactic or therapeutic vaccine and/or gene therapy-based applications. These adjuvants comprise a block copolymer and a cationic surfactant component. The inclusion of a cationic surfactant results in an increased percentage of polynucleotide that is physically... Agent: Merck And Co., Inc

20070092530 - Antibodies as t cell receptor mimics, methods of production and uses thereof: The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such... Agent: Dunlap, Codding & Rogers P.C.

20070092532 - Arthritis vaccines and methods: Vaccine compositions for preventing the onset or induction of arthritis in a subject susceptible to developing arthritis, comprising an arthritic protective peptide comprising the amino acid sequence of SEQ ID NO: 1. In various embodiments, the anti-arthritic peptide is admixed with an adjuvant in a pharmaceutically acceptable carrier. Methods include... Agent: Harness, Dickey & Pierce, P.L.C

20070092529 - Compositions and methods for diagnosing and treating cancers: Compositions and methods for diagnosing, monitoring, or treating cancers. Genes encoding transmembrane proteins that are over-expressed in colon, lung, breast, prostate, liver, stomach, esophagus, or kidney cancer tissues are identified. These transmembrane genes can be used as biological markers for the detection or diagnosis of cancers. These genes can also... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070092531 - Compositions for immunotherapy and uses thereof: The present invention relates to an immunogenic composition comprising a conjugate between an antigen and an oxidized mannan comprising mannose units and aldehyde groups, and a pharmaceutically acceptable carrier.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070092527 - Proton-sensing g-protein coupled receptors and dna sequences thereof: This invention relates to the newly identified utility of certain G protein-coupled receptors (GPCRs), in particular to OGR1, GPR4 and TDAG8 (TDAG8 is also named GPR65) polypeptides, and polynucleotides encoding such GPCR polypeptides, to their use in diagnosis and to methods of identifying compounds that are agonists or antagonists to... Agent: Novartis Corporate Intellectual Property

20070092528 - Superantigen fusion protein for anti-cancer therapy and methods for the production thereof: The present invention provides a fusion protein, comprising: a) a ligand that stimulates cancer cell growth and corresponds to receptors overexpressed by cancer cells, or a screened peptide that is affinitive to or antagonist to cancer cell receptors, or a peptide that directly interacts with cancer cell surface; b) a... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070092533 - Method of preventing t cell-mediated responses by the use of the major histocompatibility complex class ii analog protein (map protein) from staphylococcus aureus: A method of immunomodulating the T cell response in Staphylococcal bacteria is provided wherein an effective amount of the Map protein from Staphylococcus aureus is administered to a host to prevent or suppress the T cell response. The present method may be utilized with either the Map protein or an... Agent: Stites & Harbison PLLC

20070092535 - Delivery of drugs to mucosal surfaces: Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070092534 - Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.... Agent: Knobbe, Martens, Olson & Bear, LLP

20070092536 - Cold-adapted equine influenza viruses: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity,... Agent: Heska Corporation Intellectual Property Dept.

20070092537 - Compositions and methods for the treatment of canine influenza virus disease: Compositions, including vaccine compositions, and methods for treating, preventing or ameliorating canine influenza virus (CIV) disease by utilizing one or more canine influenza virus (CIV) or equine influenza virus (EIV) strain or immunogens thereof are set forth herein. Also set forth are challenge models useful in assessing the efficacy of... Agent: Wyeth Patent Law Group

20070092538 - Immunogenic reagents from west nile virus: Recombinant production of immunogenic West Nile Virus (WNV) proteins is described. These proteins, heterodimers comprising the proteins, fusions thereof, polynucleotides encoding the proteins, and combinations thereof, as well as antibodies produced therefrom, can be used in immunogenic compositions for preventing, treating and diagnosing WNV infection. Also described are highly sensitive... Agent: Novartis Vaccines And Diagnostics Inc.

20070092540 - Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof: Carboxylic-gated-nitroxide (CGN) compounds and their esterified derivatives are discovered and disclosed as compositions and shown to have the potential in treating a variety of acute and chronic diseases and disorders resulting from reactive oxygen species (ROS) injury. Compositions for treating tissue damage from ROS injury containing CGN, or active derivatives... Agent: Bozicevic, Field & Francis LLP

20070092539 - Method of preparing an aqueous meloxicam solution and aqueous solution thus produced: A method of solubilizing a selective inhibitor active agent of cyclo-oxigenase-2 (COX-2), such as meloxicam, and a method of preparing an ophthalmic solution from the solubilized meloxicam for the treatment of distinct ocular affections are described. The invention also refers to an aqueous ophthalmic solution resulting from the method, said... Agent: Knobbe Martens Olson & Bear LLP

20070092542 - Cosmetic o/w emulsion comprising 1,2-hexanediol: A cosmetic oil-in-water emulsion which comprises 1,2-hexanediol and a method of preparing same.... Agent: Greenblum & Bernstein, P.L.C

20070092541 - Direct contact quench crystallization process and cosmetic products produced thereby: A process for making a solid cosmetic composition comprising the steps of: forming at least one hot process stream comprising a solvent and a gellant dissolved therein, the hot process stream having a first temperature; forming at least one cold process stream comprising a cosmetic active having a second temperature... Agent: The Procter & Gamble Company Intellectual Property Division

20070092545 - Aerosol coolant spray for killing and removing ticks: A composition of an aerosol coolant spray for killing and removing ticks from mammal skin, to be dispensed from a pressurized a pressurized aerosol spray cannister. The aerosol coolant spray composition includes a liquid coolant material for freezing the essential oil and the cooled essential oil for immobilizing and killing... Agent: Ezra Sutton P.A.

20070092547 - Method for treating/controlling/killing fungi and bacteria: This present teaching describes how to treat substrates with novel compositions in order to limit fungi, dermatophytes, yeasts, and bacteria thereon.... Agent: Sonnenschein Nath & Rosenthal LLP

20070092544 - Natural insect repellant: Disclosed is a pesticide method and composition utilizing a mixture of cedar and cinnamon oils as active pesticide agents in an inert carrier. The composition may also utilize a surfactant. Exemplary embodiments disclosed herein may include up to 8.5% by volume of cedar oil, up to 8.5% cinnamon oil, lemon... Agent: Cislo & Thomas, LLP

20070092543 - Tablets having an emulsified polymer matrix for the controlled emission of gas, and production process: Tablets capable of producing a gas in a controlled manner for its preferred use in apparatuses intended for the administration of medicaments or serums, such that the gas exerts the control of the rate of release of the serum or medicament to the patient. The tablets comprise an emulsified polymer... Agent: Vedder Price Kaufman & Kammholz

20070092546 - Thiamin based insect repellant: The present invention provides a topical application of thiamin to human skin or mammalian coats to provide effective insect repellency. Any commercially available thiamin compounds such as thiamin hydrochloride or thiamin mononitrate can be combined with a pharmaceutically or cosmetically acceptable carrier for preparing a composition for topical application. This... Agent: LatimerIPLaw, LLP

20070092548 - Semiochemical reservoir to attract subterranean termites tunneling in soil: The present invention relates generally to polymer devices impregnated with semichemical attractants for termites. The materials for delivering the semiochemicals are preferably cellulose-free. Devices of the subject invention are placed in soil and provide a slow-release and permeation of the semiochemicals into the adjacent soil so that termites tunneling in... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070092549 - Water-soluble compound: A water-soluble magnetic anti-mitotic compound with a water-solubility of at least 100 micrograms per milliliter, a molecular weight of at least 150 grams per mole, a mitotic index factor of at least 10 percent, a positive magnetic susceptibility of at least 1,000×10−6 cgs, and a magnetic moment of at least... Agent: Buchanan, Ingersoll & Rooney PC

20070092550 - Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants: This invention discloses methods to attach and grow a monolayer of cultured human corneal endothelial cells onto the endothelial side of the stroma synthesized from biopolymer to generate a more bio-equivalent artificial cornea. The approaches will include the use of attachment and growth promoting agents such as fibronectin, laminin, RGDS,... Agent: Jacobson Holman PLLC

20070092551 - Therapeutic agent: A therapeutic agent and prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for an insulin-mimetic action, a food, beverage and feed, an agent for enhancing glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, characterized... Agent: Birch Stewart Kolasch & Birch

20070092552 - Chewable lozenge cold remedy composition and method for making same: A chewable lozenge for the treatment of cold symptoms having a zinc formulation which includes both zinc gluconate and zinc actetate.... Agent: Cynthia L Pillote Snell & Wilmer

20070092553 - Compositions and methods of making rapidly dissolving lonically masked formulations: The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug... Agent: Chalker Flores, LLP

20070092554 - Sexual dysfunction compounds: The present invention provides for a sexual dysfunction compound comprising a rapid-onset pharmaceutical composition that further comprises cocoa powder. The invention also provides for a process for manufacturing the composition, and use of the composition in sexual dysfunction therapy.... Agent: Fulbright & Jaworski, LLP

20070092555 - Thermotolerant phytase for animal feed: The invention provides a synthetic phytase polynucleotide which is optimized for expression in plants and which encodes at thermotolerant phytase, as well as isolated thermotolerant phytase enzyme. Also provided are feed or food products comprising a thermotolerant phytase, and transgenic plants which express the thermotolerant phytase. Further provided are methods... Agent: Syngenta Biotechnology, Inc. Patent Department

20070092556 - Anti-microbial material and method of making the same: A material to be used for furniture, drapery, wall covering and other similar objects in hospitals and the healthcare industry is formed of a skin with an inorganic anti-microbial compound attached to a backing. The skin includes a film impregnated with said compound and one or more layers of polyurethane... Agent: Gottlieb Rackman & Reisman PC

20070092557 - Method of preparing biodegradable dual pore polymer scaffolds for tissue engineering: There is provided a method of preparing biodegradable dual pore polymer scaffolds, comprising the steps of: maintaining a polymer solution containing a biodegradable polymer, an effervescent mixture of carbonate and organic acid, and solvent at a temperature range of −196° C. to ambient temperature so as to evaporate the solvent... Agent: Jones Day

20070092558 - Methods of preparing targeted immunoliposomes: Methods of preparing targeting ligand bound avidin-lipid vesicles for use in preparing a targeted, therapeutic liposome composition are disclosed. Each vesicle comprises an avidin molecule coupled to the polymer-conjugated biotin which retains multiple free site biotin-binding sites such that the vesicle may be used to further couple a biotinylated-targeting ligand.... Agent: Philip S. Johnson Johnson & Johnson

20070092560 - Lipophilic vehicle-based dual controlled release matrix system: A lipophilic vehicle-based dual controlled-release matrix, suitable for encapsulation in hard or soft capsules, has been developed. The matrix is in the form of a suspension, which allows for easier formulation of low dose compounds and/or compounds which are moisture sensitive. The matrix includes two rate controlling barriers for the... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070092559 - Liquid dosage forms having enteric properties of delayed and then sustained release: Pharmaceutical preparations and methods that contain enteric polymers formulated in liquid dosage forms. The preparations and methods provide enteric properties of delayed and then sustained release, without the need for expensive tableting or coating processes.... Agent: Eastman Chemical Company

20070092563 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20070092564 - Orally distintegrating formulation and process for preparing the same: An orally disintegrating formulation and its preparation are provided. The orally disintegrating formulation comprises an effective amount of a pharmaceutically active ingredient and a matrix, wherein the matrix contains an amino acid and pullulan. The orally disintegrating formulation can disintegrate rapidly in oral cavity and be taken without aid of... Agent: Darby & Darby P.C.

20070092562 - Product and process for increasing compactibility of carbohydrates: The present invention includes a method for preparing a highly compactible carbohydrate product, and the product itself. In one embodiment, a composition according to the present invention is a quick-dissolving composition that includes polyols.... Agent: Morgan, Lewis & Bockius LLP

20070092561 - Water-soluble aspirin composition: Compositions in which aspirin is present in combination with alkaline compounds, especially those containing water of crystallization (hydrates), deteriorate on standing. This deterioration may take several forms: It can be a physical deterioration in which such aspirin compositions become completely unmanageable, wet, gummy, sticky masses; or chemical decomposition in which... Agent: Cermak & Kenealy LLP

20070092565 - Gastric retention drug delivery system: A gastric retention drug delivery system (i.e. a controlled release drug dosage form) formulated so as to promote retention of the dosage form in the upper gastrointestinal tract and in particular the stomach.... Agent: Bcf LLP 25th Floor

20070092566 - Oral sustained-release tablet: An oral sustained-release tablet is provided, which does not cause initial rapid increases in the bloodlevels of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (KRP-197) and can maintain constant the blood levels. (Solving means) An oral sustained-release tablet comprises a pharmaceutical composition and a gel-forming material, the pharmaceutical composition containing KRP-197 as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070092567 - Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin: A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterised in that the difference, in absolute value, between the times of maximal concentration (Tmax) of Pravastatin and Fenofibric acid is not less than 1.5 hours upon administration with food to humans.... Agent: Merchant & Gould PC

20070092569 - Extended release formulation of levetiracetam: The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible... Agent: Blank Rome LLP

20070092568 - Galantamine compositions: The present invention relates to controlled release compositions of galantamine, processes to prepare the compositions, their in-vitro release profiles and method of use and method of treatment using the said compositions.... Agent: Dr. Reddy's Laboratories, Inc.

20070092570 - Drug delivery device: Drug delivery devices, and methods of delivering pharmaceutically active agents to a target tissue within a body using such devices, are disclosed. One drug delivery device includes a body having an internal surface for disposing on a target tissue and a well having an opening to the internal surface. An... Agent: Alcon

20070092571 - Non-irritating formulation and method for the intradermal delivery of substances: This invention describes a composition of matter to facilitate intra-dermal delivery of a great variety of active substances, especially including high molecular weight cosmicuticals. Also disclosed is a method of forming the composition of matter and applying topically to patients, especially using a cream or patch. The active substance is... Agent: Robert J. Van Der Wall Gables One Tower

20070092572 - Bone cement compositions and the like comprising an rnaiii-inhibiting peptide: RNAIII-inhibiting peptide (RIP) advantageously treats or reduces the risk of biofilm formation on implanted bone cement, thus reducing the possibility of sustained chemotherapy, hospitalization, or surgical removal of the bone cement. Avoiding sustained chemotherapy reduces the risk of inducing antibiotic resistance. Accordingly, RIP can be used with antibiotics that otherwise... Agent: Merchant & Gould PC

20070092573 - Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist: The present invention is a new stable extended release drug composition particularly suitable for use as a beta-adrenoreceptor antagonist agent. The present invention is specifically a drug composition comprising a pharmaceutical, a methacrylic acid copolymer and a matrix forming agent, and a method for manufacturing same. When applied to highly... Agent: Peacock Myers, P.C.

20070092576 - Compositions containing opioid antagonists: Compositions containing opioid antagonists are disclosed, particularly alvimopan and its active metabolite in solid dosage forms, where the drug is uniformly distributed, achieves the desired bioavailability, and is stable. Methods of preparing and using the compositions containing opioid antagonists are also disclosed. The results are achieved by a combination of... Agent: Woodcock Washburn LLP

20070092575 - Compositions for administering rnaiii-inhibiting peptides: Compositions comprising RIP are advantageously formulated in compositions allowing sustained release and protection from degradation, and improved therapeutic efficacy. To that end, RIP compositions may be delivered to the skin or mucosal membranes as a salve or the like. Alternatively or additionally, RIP compositions may be administered in polymeric nanoparticle... Agent: Merchant & Gould PC

20070092574 - Controlled released compositions: The compositions disclosed herein are for use as controlled release therapeutics for the treatment of a wide variety of diseases. In particular, the compositions provide water soluble bioactive agents, organic ions and polymers where the bioactive agent is efficiently released over time with minimal degradation products. The resulting controlled release... Agent: Jennifer M Mccallum, Ph D, Esq The Mccallum Law Firm, LLC

20070092577 - Dietary calcium for reducing the production of reactive oxygen species: The subject application provides a method of identifying or screening compounds or compositions suitable for reducing the production of reactive oxygen species (ROS) comprising: a) feeding (or orally administering) compositions comprising dietary material containing dietary calcium (or dietary calcium) to at least one subject; b) measuring intracellular concentrations of calcium... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070092578 - Skin rejuvinating supplement: A skin rejuvenating supplement composition for treating age spots, darkening of the skin, dry skin, calcium amino acid deficiencies, osteoporosis and eye site deficiencies. The composition contains 100 to 1,500 mg of pearl powder, 0.6 to 50 μkg Vitamin D, 1.5 to 20.0 mg of astaxanthin and 20 to 750... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070092579 - Medical products and parenteral formulations: A medical product and parenteral formulation are provided. The parenteral formulation is preferably for fluid restricted patients such as pediatric patients and can include amino acids, lipids, carbohydrates and electrolytes. The parenteral formulation can be housed in a multi-chamber container for separately storing a amino acid component, a lipid component... Agent: Baxter Healthcare Corporation

20070092580 - Dual-phase cement precursor systems for bone repair: Disclosed are dual-phase cement precursor systems and related methods and kits. The cement precursor systems are composed of a first and second discrete phases, at least one of which is aqueous. When combined, the cement precursor phases form a cement that is suitable as a bone graft material for bone... Agent: Banner & Witcoff, Ltd.

20070092581 - Hydrogen cyanamide pesticide formulations: Agricultural crops are protected from the growth of undesirable vegetation as well as nematode and insect infestations, by the application of hydrogen cyanamide in combination with a short-chain, water-soluble monocarboxylic acid, with improved pesticidal effect.... Agent: Townsend And Townsend And Crew, LLP

20070092582 - Methods of preserving ophthalmic solutions and preserved ophthalmic solutions: A preservative system for aqueous ophthalmic solutions is provided, where the preservative system comprises a hydrogen peroxide source, at least one hydrogen peroxide stabilizer and an alkali earth metal salt.... Agent: Novartis Corporate Intellectual Property

20070092583 - Cold remedy composition comprising zinc salts: A composition to treat symptoms of cold and/or prevent the onset of cold symptoms and methods of forming and using the composition are disclosed. The composition is formulated to maintain one or more active ingredients in association with an oral membrane for an extended period of time. The invention further... Agent: Snell & Wilmer L.L.P. (main)

20070092584 - Combinations of chromium with antidiabetics for glucose metabolism disorders: Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070092585 - Cancer chemotherapy compositions comprising pi3k pathways modulators and triptolide: The present invention provides compositions and methods for inhibiting growth of and/or killing cancer cells. The compositions include: an inhibitor of the PI3K signal transduction pathway, and additional agents, such as Triptolide.... Agent: Mandel & Adriano

20070092586 - Compositions and methods for the administration psychotropic drugs which modulate body weight: Embodiments of the invention describe compositions and methods for the administration of fast disintegrating atypical antipsychotics, metabolites of atypical antipsychotics, and antidepressants which reduce weight in patients previously taking conventional formulation of atypical antipsychotics and antidepressants. In a preferred embodiment said fast dissolving atypical antipsychotic is FAZACLO. In another preferred... Agent: Knobbe Martens Olson & Bear LLP

20070092587 - Extract from plant of japanese parsley family and process for producing the same: The present invention provides an extract obtainable by extracting a plant belonging to Umbelliferae, or a processed product thereof, with a water-containing alcohol; a process for preparing the extract; a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response and/or... Agent: Birch Stewart Kolasch & Birch

20070092588 - Soy milk made from germinated soy beans: Soymilk is provided which can prevent or alleviate menopausal disorders, and is highly safe with no risk of side effects even with long-term intake thereof. This soymilk is made from germinated soybeans, and is used for alleviating or preventing the vasomotor disorder-like symptoms and psychoneuropathic disorder-like symptoms associated with menopausal... Agent: David B. Ritchie Thelen Reid & Priest, LLP

20070092589 - Veterinary pharmaceutical compositions for gastric ulcers: y

20070086944 - Conjugates of antioxidants with metal chelating ligands for use in diagnostic and therapeutic applications: The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes.... Agent: Kramer Levin Naftalis & Frankel LLP

20070086943 - Epha2 agonistic monoclonal antibodies and methods of use thereof: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2... Agent: Jones Day

20070086942 - Methods and compositions for generating bioactive assemblies of increased complexity and uses: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD)... Agent: Faegre & Benson LLP Patent Docketing

20070086945 - Preparations for diagnosis of pancreatic exocrine function: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070086946 - Assay: The present invention relates, in general, to a method of assaying an immune response induced by an immunogen, and, more particularly, to a method of assaying a immunogen for its ability to induce a desired immune response, wherein the assay is effected in an autoimmune animal.... Agent: Nixon & Vanderhye, PC

20070086947 - System and method for selecting a pillow and mattress: A method is provided for selecting a pillow and mattress based upon an empirical measurement of an individual's pillow selection criteria, mattress selection criteria and sleep characteristics. A system incorporating the principles of the method are also disclosed.... Agent: Thompson Coburn, LLP

20070086948 - Tissue metabolic stress monitoring: Various pathophysiological states are determined by evaluating the rate of 17O-containing water production oxygen using proton MRI. The method can be used to identify viable but threatened myocardium, injured by viable muscle, penumbra tissue in a stroke patient, and the like.... Agent: Dickstein Shapiro LLP

20070086950 - Gat2 transporters expressed in blood brain barrier cells: GAT2 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the GAT2 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in... Agent: Townsend And Townsend And Crew, LLP

20070086949 - Method of bioimaging using nanocrystals of fluorescent dyes: This invention provides nanocrystals or polymer doped nanocrystals of hydrophobic organic fluorescent dyes as stable dispersions in an aqueous system. The dispersions can be prepared without stabilizers such as surfactants and the like. The aqueous dispersions of the nanocrystals or the polymer doped nanocrystals can be used for bioimaging.... Agent: Hodgson Russ LLP

20070086951 - Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments: i

20070086953 - Medicinal aerosol formulation products with improved chemical stability: The present invention relates to a medicinal aerosol formulation product with improved chemical stability. The product is a pressurized metered dose inhaler including an aerosol canister equipped with a metering valve provided with sealing rings and/or gaskets made of a vulcanisate of an elastomeric composition of a butyl rubber, a... Agent: Holme Roberts & Owen, LLP

20070086954 - Method and apparatus for treatment of respiratory infections by nitric oxide inhalation: Methods for suppressing, killing, and inhibiting pathogenic cells, such as microorganisms associated with a respiratory infection within the respiratory tract of an animal are described. Methods include the step of exposing the pathogenic cells to an effective amount of nitric oxide, such as through inhalation of nitric oxide gas, in... Agent: Sidley Austin LLP Suite 4000

20070086952 - Rapid acting and prolonged acting inhalable insulin preparations: It has been discovered that by combining a chelator, such as ethylenediaminetetraacetic acid, with an acidifier, such as citric acid, the insulin is absorbed much more rapidly than in the absence of the chelator and acidifier, with a commercially available rapid, intermediate or long lasting insulin such as glargine, one... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070086957 - Combination of medicaments for the treatment of respiratory diseases: R3 is hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, or O—C1-4-alkylene-COO—C1-4-alkyl, or an enantiomer, mixture of enantiomers, or racemate thereof, or an acid addition salt with pharmacologically acceptable acids thereof, or a solvate or hydrate thereof; and (b) another active substance 2, wherein the molar ratio of the compound of formula... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070086955 - Form of administration for controlling primary headaches: The invention relates to a nasally applied, film-shaped, bioadhesive pharmaceutical form of administration containing at least one agent-containing layer that is based on crosslinked hydrophilic polymers comprising up to 60 percent by weight of Lidocaine, the percentage being in relation to the total quantity of crosslinked hydrophilic polymers. Also disclosed... Agent: Frommer Lawrence & Haug

20070086958 - Formation of medically useful gels comprising microporous particles and methods of use: Compositions and methods use the gel-forming properties of microporous particles to create useful formulations combining two free-flowing materials to produce a hydrogel mass. The free-flowing materials preferably provide dry microporous particles (preferably as an aerosol) that may contain additional agents, and a second composition of a fluid material which is... Agent: Mark A. Litman & Associates, P.A.

20070086956 - Method for accelerating the rate of mucociliary clearance: The instant invention provides for a composition and method for using Kunitz-type serine protease inhibitors, e.g., aprotinin or bikunin, for stimulating the rate of mucociliary clearance of mucus and sputum in lung airways of subjects afflicted with mucociliary dysfunctions such as cystic fibrosis.... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20070086959 - Use of a compositionally gradient copolymer in an aerosol device comprising two compartments, and aerosol device comprising said copolymer and a compressed gas: The invention relates to an aerosol device with two compartments, which contains the following: (a) in a first compartment, a hair treatment composition comprising, in a cosmetically-acceptable aqueous medium, at least one compositionally-graded copolymer comprising at least two different monomers and having a mass polydispersity index (Ip) of less than... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070086960 - Systems and methods for enhancing the appearance of teeth: Effective, non-invasive and non-destructive systems and methods provide an appearance of increased whiteness and/or brightness of the teeth, thereby enhancing the appearance of the teeth. One or more residual colors or dyes are applied to the surface of a tooth in order to complete the color spectrum of the tooth... Agent: Kirton And Mcconkie

20070086961 - Tooth whitening substances: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division

20070086962 - Stable sunscreen composition: A stable sunscreen composition comprising: (i) an organic UV-A sunscreen; (ii) an organic UV-B sunscreen; and (iii) cosmetically acceptable vehicle wherein said UV-A sunscreen and UV-B sunscreen are kept isolated from each other by encapsulating one of said sunscreens in solid lipid encapsulate, the solid lipid encapsulate comprising a lipid.... Agent: Unilever Intellectual Property Group

20070086963 - Apparatus to apply a hair care preparation: A method for coloring hair with a hair care formulation that is mixed prior to use is provided. The method includes mixing together the components of the hair care formulation as the formulation is dispensed from a plastic applicator having at least one storage compartment for each component and a... Agent: Bereskin And Parr

20070086965 - Chromonic nanoparticles containing bioactive compounds: A chromonic nanoparticle mixture prepared by combining (i) a continuous water-soluble polymer phase and (ii) a discontinuous chromonic phase comprising a chromonic material; and non-covalently crosslinking the resulting chromonic nanoparticles with a polyvalent cation salt.... Agent: 3m Innovative Properties Company

20070086964 - Method for making chromonic nanoparticles: A chrmonic nanoparticle mixture prepared by combining (i) a continuous water-soluble polymer phase and (ii) a discontinuous chromonic phase comprising a chromonic material; and non-covalently crosslinking the resulting chromonic nanoparticles with a polyvalent cation salt.... Agent: 3m Innovative Properties Company

20070086966 - Cosmetic product containing mineral water for remineralising and rejuvenating the skin: The invention relates to a cosmetic composition that can be used to remineralise human skin and to counteract the effects of ageing on the latter. According to the invention, said composition contains 0.5-3% water of volcanic origin containing 0.01-0.05 mg/l Fe, 100-300 mg/l K, 1,000-2,000 mg/l Na, 80-200 mg/l Mg,... Agent: Akerman Senterfitt

20070086967 - Treatment of psoriasis with rosiglitazone: Disclosed is a method of treatment of psoriasis which comprises administering to a patient in need thereof by the oral route a pharmaceutical composition comprising rosiglitazone, or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, wherein the method comprises administering 2 to 8 mg rosiglitazone... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070086968 - Hydrolysis resistant organomodified disiloxane surfactants: s

20070086969 - Miracle hair treatment: A composition for the treatment of hair. The composition consists essentially of mayonnaise being present in the composition in a concentration of between about 55 and 64 percent by weight. Olive oil is present in the composition in a concentration of between about 12 and 15 percent by weight, carrot... Agent: James Ray & Associates

20070086970 - Hair cleansing compositions: A hair cleansing composition comprises the following ingredients (A) to (C): (A) a dicarboxylic acid or hydroxydicarboxylic acid, or a salt thereof, (B) an organic solvent, and (C) an anionic surfactant having a sulfate group; and has a pH of from 1 to 4 when diluted 20-fold by weight with... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070086971 - Acidic cleaning compositions: A composition comprising a mixing product of: (i) a first acid having a pKa of less than 3, in an amount by weight of 1-10%, (ii) a second acid having a pKa of greater than 3, in an amount by weight of 1-10%, (iii) a nonionic surfactant in an amount... Agent: Colgate-palmolive Company

20070086972 - Hair growth compositions and methods for treating hair loss or related conditions: The present invention relates to hair growth compositions as well as to methods for treating hair loss or related conditions.... Agent: Jacob Birnbaum

20070086974 - Cetirizine compositions: Stable and palatable taste masked pharmaceutical compositions of substituted benzhydrylpiperazines and processes for preparing them.... Agent: Dr. Reddy's Laboratories, Inc.

20070086976 - Acyclic n-halamines in antibacterial materials: The present invention provides biocidal polymers having N-halamine technology incorporated therein, which are useful for a wide range of applications. The microbiocidal polymer can be a homopolymer, a co-polymer or a grafted polymer. In certain aspects, the present invention provides polymers from acrylic amine-monomers such as acrylamide, which monomers readily... Agent: Townsend And Townsend And Crew, LLP

20070086977 - Method of treating dermatological conditions: A method of treating a patient having a dermatological condition which comprises administering to the patient a composition comprising a complex characterized as having a maximum water solubility of about 5 wt. % and further characterized as being a complex that is formed by a metathesis reaction between a bioactive... Agent: Law Offices Of Jack Matalon

20070086975 - Polymeric micellar complexes and drug delivery vehicles thereof: Disclosed are complexes of an amphiphilic copolymer, wherein the amphiphilic copolymer has benzoyl sulfonic acid groups on the hydrophobic segment of the copolymer.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070086973 - Drug delivery systems for photodynamic therapy: The invention is generally related to the field of photodynamic therapy by use of photosensitizers and stabilized formulations of the photosensitizers. These formulations may be used to deliver a photosensitizer as a pharmaceutical, agricultural, or industrial agent. The photosensitizer containing formulations and compositions of the invention comprise one or more... Agent: Morrison & Foerster LLP

20070086978 - Colon cleansing compositions and methods: A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate,... Agent: Leon R. Yankwich Yankwich & Associates, P.C.

20070086979 - Methods and compositions for use in treatment of patients with autoantibody positive disease: The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070086980 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070086981 - Delivery peptides, their constructs with active agents and use: The present invention refers to delivery proteins, protein-cargo complexes, methods, and means for the enhanced delivery or transport of drugs, biologically active agents or other compounds as cargo or cargo molecules onto, into, or across biological membranes or tissues forming a biological barrier.... Agent: Ostrolenk Faber Gerb & Soffen

20070086983 - Endothelium-targeting nanoparticle for reversing endothelial dysfunction: The present invention includes delivery of isolated and purified nucleic acids that encode GTPCH proteins in nanoparticles for the treatment of endothelial cells damaged by diabetes, smoking, dyslipidemia, hypertension, and cardiovascular disease. The nanoparticles contain a nucleic acid sequence, polymer and a targeting ligand. The targeting ligand facilitates the selective... Agent: Medlen & Carroll, LLP

20070086982 - Gene therapy for regulating smooth muscle tone: The present invention is directed towards a method of regulating smooth muscle tone, comprising the introduction, into smooth muscle cells of a subject, of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth... Agent: Amster, Rothstein & Ebenstein LLP

20070086985 - Vectors for tissue-specific replication: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per... Agent: Dla Piper US LLP

20070086984 - Viruses for the treatment of cellular proliferative disorders: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus,... Agent: Fish & Richardson P.C.

20070086988 - Insulin expressing human pancreatic islet cell line capable of reversibly proliferating and use thereof: A reversibly immortalized human pancreatic islet cell line containing an hTERT gene and an SV40T gene each interposed between a pair of LoxP sequences, characterized in that it is capable of producing insulin and enhancing expression of insulin after excising the hTERT gene and the SV40T gene, in particular, NAKT-13... Agent: Nath & Associates

20070086989 - Prosthetic grafts: An improved prosthetic graft for the bypass, replacement or repair of vessels and organs that are in contact with blood flow is disclosed. The prosthetic graft includes a porous prosthetic implant and adherent cells adhered to the outer surface of the implant. The adherent cells are transfected with at least... Agent: Williams, Morgan & Amerson

20070086990 - Table olives containing probiotic microorganisms: The invention relates to table olives enriched with probiotic microorganisms, in particular lactobacilli and bifidobacteria, food products containing them and a method for their preparation. The olives and food products of the invention provide an amount of microorganisms sufficient to exert a beneficial action on the gastro-intestinal tract and are... Agent: Kenyon & Kenyon LLP

20070086991 - Use of strains of lactobacillus and by-products thereof for inhibiting formation of blood vessels: A lactic composition containing at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus casei and a mixture of Lactobacillus acidophilus and Lactobacillus casei, and a whole broth of the bacterial strain or the mixture of the bacterial strains, is useful for the prevention or treatment... Agent: Godfrey & Kahn S.c.

20070086986 - Preparation of three-dimensional mammalian ovarian follicular cell and ovarin follicle culture systems in a biocompatible matrix: A process for encapsulating and immobilising mammalian stem cells, ovarian follicular cells, gametes, ovarian follicles or mammalian embryos which are able to auto-organise into three-dimensional structures in vitro, and express biological functions in a manner similar to that which is observed in the organism in vivo is described. The capsules... Agent: Dickstein Shapiro LLP

20070086987 - Skeletal musle-derived cells and methods related thereto: The disclosure provides methods of propagating skeletal muscle cell (SkMC) cultures enriched in differentiation-competent myoblasts that express normal levels of CD56 and reduced levels of desmin. The methods comprise culturing SkMCs in a mitogen-rich cell culture medium supplemented with TGF-β. The disclosure also provides therapeutic methods utilizing SkMCs propagated in... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070086992 - Cascade: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumour immune response in a human patient.... Agent: Townsend And Townsend And Crew, LLP

20070086993 - Use of modified lysozyme c to prepare medicinal compositions for the treatment of some serious diseases: Use of modified lysozyme c or its pharmaceutically acceptable salts and its industrial production for the preparation of medicinal compositions, suitable for oral, parenteral and topical administration, for prophylaxis and therapy of some serious diseases in mammalians.... Agent: Standley Law Group LLP

20070086994 - Anti-nik antibodies and uses thereof: An antibody or antibody preparation being capable of specifically binding the amino acid sequence of NF-&kgr;B-inducing kinase (NIK) MAP3K14, or a specific portion thereof, and of thereby regulating a biochemical activity of NIK, and/or enabling detection of NIK or a specific portion thereof.... Agent: Marshall, Gerstein & Borun LLP

20070086995 - Methods of treating ige-mediated disorders comprising the administration of high concentration anti-ige antibody formulations: The present application relates to methods of treating IgE-mediated disorders comprising the administration of highly concentrated anti-IgE antibody formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration.... Agent: Genentech, Inc.

20070086996 - Biodegradable t-cell activation device and methods: A biodegradable device for activating T-cells includes a biodegradable support and a binder attached to the biodegradable support, the binder having reactivity to one or more agents capable of binding to a T-cell surface antigen.... Agent: Westman Champlin & Kelly, P.A.

20070086997 - Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes: The present invention concerns thirteen novel variants of alternative splicing of the obesity and/or diabetes related genes.... Agent: Potter Anderson & Corroon LLP Attn: Kathleen W. Geiger, Esq.

20070086998 - Therapeutic human anti-mhc class ii antibodies and their uses: The instant invention relates to methods, compositions, uses related to the compositions and pharmaceutical packages for treating a disorder involving cells expressing MHC class II antigens using a combination of a human antibody-based antigen-binding domain that binds to a human Class II MHC molecule, and an antibody-based antigen-binding domain that... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070087000 - Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of... Agent: Fitzpatrick Cella Harper & Scinto

20070087002 - Anticholesterol immunoglobulin to treat lipid raft diseases: Immunoreactive compositions and methods for immunizing animal, including, humans, cows, and fowl, against cholesterol and cholesterol derivatives, including cholesterol oxides, and their use in methods for reducing and preventing lipid raft-based diseases, including, but not limited to HIV-1, SARS, prion formation in Creutzfeldt-Jakob disease, and neutralizing oxidized modified lipoproteins, specifically,... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070086999 - Compositions and methods including a recombinant human mab that promotes cns remyelination: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise... Agent: Klauber & Jackson

20070087001 - Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis: The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or... Agent: Faegre & Benson LLP Patent Docketing

20070087003 - Methods of treating a blood pathology using anti-tnf antibodies and fragments thereof: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070087005 - Anti-glypican-3 antibody: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues.... Agent: Fish & Richardson PC

20070087006 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20070087007 - Compounds, compositions and methods for the treatment of diseases characterized by a-33 related antigens: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer, and nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing such antigens PRO301, PRO362 or PRO245.... Agent: Heller Ehrman LLP

20070087004 - Pro104 antibody compositions and methods of use: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro 104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit Another... Agent: Licata & Tyrrell P.C.

20070087008 - Rab9a, rab11a, and modulators thereof related to infectious disease: Disclosed herein are methods of reducing infection of a cell by a pathogen, for example to treat or prevent a pathogen infection. Exemplary pathogens include those that use a lipid raft. The disclosure also relates to methods of identifying agents involved in pathogen infection, such as modulators of Rab9A and... Agent: Klarquist Sparkman, LLP

20070087010 - Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders: Treatment and/or prophylaxis, in mammalian patients, of neurodegenerative and other neurological medical disorders is effected by administering to the patient effective amounts of apoptotic bodies and/or apoptotic cells, preferably those derived from the patient's own white blood cells, e.g. by extracorporeal treatment of the patient's blood cells to induce apoptosis... Agent: Foley & Lardner LLP

20070087009 - Immunostimulant composition comprising at least one toll-like receptor 7 or toll-like receptor 8 agonist and a toll-like receptor 4 agonist: The invention relates to an immunostimulant composition comprising at least one Toll-like receptor 7 or Toll-like receptor 8 agonist and a Toll-like receptor 4 agonist. The inventive composition can also comprise a vaccine antigen.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070087011 - Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.... Agent: Mueting, Raasch & Gebhardt, P.A.

20070087012 - Novel therapeutic target for protozoal diseases: A novel Fasciclin Related Adhesive Protein (FRAP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. FRAP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, FRAP catalyzes the... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070087013 - Orally-administered live bacterial vaccines for plague: The invention provides live, attenuated Salmonella bacterial strains that express one or more plague antigens of Yersinia pestis for use in live vaccine compositions that can be orally administered to an individual to protect against plague.... Agent: Leon R Yankwich Yankwich & Associates

20070087014 - Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections: Immunogenic polysaccharide-protein conjugates having a polysaccharide antigen (or its oligosaccharide fragment representing one or more antigenic epitopes) derived from a nosocomial pathogen conjugated to a staphylococcal surface adhesin carrier protein are used in immunogenic compositions to elicit antibody responses to both the polysaccharide antigen and the staphylococcal surface adhesion carrier... Agent: Hunton & Williams LLP Intellectual Property Department

20070087016 - Interleukin-12 as an adjuvant for paramyxoviridae vaccines: A method is disclosed of reducing viral replication of a virus of the paramyxoviridae family in a host, comprising administering to the host an antigen of the virus in combination with an effective adjuvant amount of interleukin-12 (IL-12). Human viruses of the paramyxoviridae family include paramyxoviruses (e.g., parainfluenza virus 1,... Agent: Wyeth/finnegan Henderson, LLP

20070087015 - Multivalent dengue virus vaccine: The present invention provides vaccine compositions of attenuated dengue virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against all four dengue virus serotypes by administration of attenuated dengue-1,... Agent: U.s. Army Medical Research And Materiel Command

20070087018 - Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic... Agent: Howson And Howson

20070087017 - Ultrafiltration for preparing outer membrane vesicles: In place of a step of centrifugation during preparation of outer membrane vesicles (OMVs) from bacteria, the invention utilises ultrafiltration. This allows much larger amounts of OMV-containing supernatant to be processed in a much shorter time. Thus the invention provides a process for preparing bacterial OMVs, comprising a step of... Agent: Novartis Vaccines And Diagnostics Inc.

20070087019 - Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof: The invention discloses the Moraxella catarrhalis outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding OMP106 polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention... Agent: Foley And Lardner LLP Suite 500

20070087020 - Use of parasitic biological agents for prevention and control of allergic and other ige-mediated disorders: The present invention describes using, on a repetitive basis, a non-human colonizing helminth compound, in an amount sufficient to establish a transitory parasitic helminth infection and or to simulate in a parasitic helminth infection, thereby having immunosuppressive effect against benign antigens and or stimulating a regulatory immune response characterized by... Agent: Kelley Drye & Warren LLP

20070087021 - Method of protecting against chronic infections: e

20070087022 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20070087023 - Polymer-based antimicrobial agents, methods of making said agents, and applications using said agents: The present invention relates to antimicrobial agents, methods for the production of these agents, and the use of these agents. The antimicrobial agent of the present invention includes a water-soluble polymer and oligodynamic metal ions which interact with counter-ions of the polymer such that the metal ions are bound to... Agent: Gordon & Jacobson, P.C.

20070087024 - Article comprising fibers embedded in a glassy protein: The application relates to an object (30) having a plurality of elongate elements (10) embedded in a matrix (20). The matrix (20) is made from a glassy protein, preferably including serines. The elongate elements can be fibres such as polymers fibrous protein, glass fibres, carbon fibres, carbon nanotubes and montmorilonite... Agent: Intellectual Property / Technology Law

20070087031 - Curable bone substitute: A novel composition, kit, and method of using the composition as a bone substitute for dental, orthopedic and drug delivery purposes. Specifically, the bone substitute comprises a plurality of polymeric beads having a crosslinkable shell where the shell is cured by light and/or chemical curing.... Agent: Darby & Darby P.C.

20070087026 - Drug-eluting tissue marker: A drug-eluting tissue marker for marking a site in a tissue mass comprises a drug-eluting portion having a drug for timed release to the site and a material that can be imaged using an imaging technique.... Agent: Mcgarry Bair PC

20070087027 - Electrospun skin capable of controlling drug release rates and method: A versatile covering process enabled through the identification and manipulation of a plurality of variables present in the electrospinning method of the present invention. By manipulating and controlling various identified variables, it is possible to use electrospinning to predictably produce thin materials having desirable characteristics. The fibers created by the... Agent: Inskeep Intellectual Property Group, Inc

20070087028 - Intraluminal devices for the prevention and treatment of vascular disease: An intralumen medical device comprising anti-inflamatory and anti-thrombotic or anti-coagulant drugs, agents or compounds may be utilized in the treatment of vascular disease. The intralumen medical device is selectively coated with the drugs, agents or compounds for local delivery, thereby increasing their effectiveness and reducing potential toxicity associated with systemic... Agent: Philip S. Johnson Johnson & Johnson

20070087029 - Localized delivery to the lymphatic system: The present invention provides methods for the localized delivery of an agent to the lymphatic system, including localized delivery to a lymphatic capillary bed.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20070087030 - Product for controlling dissolving rate of orthopedic implant material and process of producing the same: A product controlling dissolving rate of biomedical orthopedic implant material and a process of manufacturing the same are disclosed. At constant temperature and humidity and under vacuum, treatment solution is forced to diffuse to the material to form a second phase as a means of controlling the dissolving rate. Different... Agent: Rosenberg, Klein & Lee

20070087025 - Reiteratively layered medical devices and method of preparing same: A method for preparing a nitric oxide-releasing substrate that includes contacting an amine-functionalized silane with a substrate, contacting at least one additional amine-functionalized silane with the substrate, and contacting the substrate with nitric oxide, and repeating these steps if and as desired to produce a coating of the desired thickness... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070087032 - Composition of cartilage therapeutic agents and its application: A cartilage therapeutic composition is developed for clinical transplantation into articulatio genu (knee joints) or ankle joints. It has clinical significance for symptomatic cartilage defects of the femoral condyle (medial, lateral, or trochlear) and bone cartilage defects of the talus (anklebone) in human or animal hosts, The cartilage therapeutic composition... Agent: Gwips Peter T. Kwon

20070087034 - Drug delivery system and method of manufacturing thereof: In one embodiment, a drug delivery system and method provide a member including a combination of a drug substance and a polymer or other material, and an encapsulating layer formed in an outer surface of the member by gas cluster ion beam irradiation of the outer surface of the member,... Agent: Burns & Levinson, LLP (formerly Perkins Smith & Cohen LLP)

20070087033 - Self-fixating scaffolds: A self-fixating scaffold delivers therapeutic material to tissue for treating various diseases/conditions. A scaffold holds the therapeutic material and is implanted into the tissue. A fixation element anchors the scaffold in the tissue making the scaffold less likely to become dislodged.... Agent: Medtronic, Inc.

20070087036 - Edible film for transmucosal delivery of nutritional supplements: In one embodiment of the present invention a composition is provided comprising a film layer wherein the film layer rapidly dissolves in an oral cavity and a coating comprising a powder matrix, wherein the coating is applied to at least one side of the film layer and wherein the powder... Agent: Perkins Coie LLP

20070087038 - Gelling compositions and methods: A method for the administration of a composition that augments the acidity of gastric fluid such that intra-gastric gelation of the polysaccharide:acid soluble multivalent cation formulation is initiated independent of endogenous acid secretion. The composition includes:(a) at least one of a polysaccharide, modified polysaccharide, or polysaccharide salt, each capable of... Agent: Knoble, Yoshida & Dunleavy

20070087035 - Nutritional composition for wound healing: A nutritional composition for promoting wound healing comprises a protein source, a lipid source and a carbohydrate source wherein no more than 1.8% of the total calories of the composition derive from arginine and wherein the protein source includes proline in an amount of at least 3% of the total... Agent: Bell, Boyd & Lloyd LLP

20070087037 - Stimulation of cpt-1 as a means to reduce weight: This invention provides methods and compositions for inducing weight loss and maintaining optimum weight comprising administering an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity to the patient in need, including human patients. These methods do not require inhibition of fatty acid synthesis. In particular, this invention provides methods for... Agent: Hunton & Williams LLP Intellectual Property Department

20070087039 - Mineral collagen chelates and methods of making and using same: Collagen peptide chelated mineral products, pharmaceutical formulations thereof and methods for preparing same are provided. Also provided is a method for generating the optimal size of collagen peptide for optimum mineral chelation as well as optimum biological function for supporting bone health and joint health. Also disclosed are methods of... Agent: Kaplan Gilman Gibson & Dernier L.L.P.

20070087040 - Oil cleaning sheets for makeup: To provide an oil cleaning sheet for makeup which has excellent oil absorption, allows clear assessment of the oil absorbing effect by becoming transparent upon oil absorption, thus providing the user with a feeling of adequate wiping and a sense of satisfaction, has an agreeable feel, is resistant to damage... Agent: 3m Innovative Properties Company

20070087041 - Waterless lotion and lotion-treated substrate: A lotion includes a micro-emulsion composition, which is liquid at room temperature and undergoes a phase change to a semi-solid or solid upon contact with a substrate. The micro-emulsion composition can include a polar emollient, a non-polar emollient, a non-ionic surfactant, and a co-surfactant. The invention also includes a substrate... Agent: Patent Group Ga030-43 Georgia-pacific LLC

20070087042 - A shroud for surrounding a problem tissue for promoting healing of problem tissue adjacent healthy skin: A shroud for disposal on healthy skin tissue surrounding a problem tissue and for promoting one of an open-closed environment around the problem tissue includes a relatively rigid plastic member having an outer peripheral flange surface configured for disposal adjacent the skin surrounding the problem tissue, wherein the flange can... Agent: A Patent Lawyer Corp, PC R William Graham

20070087043 - Nicotine transdermal preparation and production method thereof: The present invention provides a production method of a nicotine transdermal preparation, which is capable of producing a nicotine transdermal preparation conveniently and economically, while maintaining highly precise content uniformity, which is capable of producing a preparation simultaneously achieving fixedness and a soft feeling during adhesion, associated with reduced skin... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070087044 - Transdermal method and patch for emesis: e

20070087047 - Enhanced circulation effector composition and method: A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment... Agent: Perkins Coie LLP

20070087045 - Lipid carrier and method of preparing the same: A lipid carrier. The carrier includes a lipid based particle comprising a cationic lipid, a cholesterol, a neutral phospholipid, and a neutral lipid, wherein the cationic lipid is about 100 parts by weight, the cholesterol is about 25˜100 parts by weight, the neutral phospholipid is about 25˜100 parts by weight,... Agent: Birch Stewart Kolasch & Birch

20070087046 - Use of green porphyrins to treat neovasculature in the eye: Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.... Agent: Goodwin Procter LLP Patent Administrator

20070087049 - Multi-component pharmaceutical dosage form: A multi-component pharmaceutical dosage form comprising a plurality of drug substance—containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070087048 - Oral dosage combination pharmaceutical packaging: A pharmaceutical delivery package comprising fixed unit dose quantities of two or more different active pharmaceutical ingredients (a) combined in a single delivery package, and (b) segregated from one another within said package wherein said package comprises a core containing a first active pharmaceutical ingredient surrounded at least in part... Agent: Norman P. Soloway Hayes Soloway P.C.

20070087050 - Orally disintegratable simvastatin tablets: An orally disintegratable tablet containing simvastatin and silicified microcrystalline cellulose is provided with a non-alkaline lubricant.... Agent: SynthonIPInc

20070087051 - Pharmaceutical composition: A method of treating a cyclooxygenase-2 dependent disorder or condition comprising administering a solid formulation of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid which has a residual moisture within predetermined levels.... Agent: Novartis Corporate Intellectual Property

20070087052 - Effervescent bisphosphonate formulation: An effervescent formulation of alendronate contains an acid source, a carbonate source, a binder, a lubricant and optionally, flavoring agents, colorants and sweeteners.... Agent: Merck And Co., Inc

20070087054 - Effervescent formulations of oxytocin: An effervescent formulation comprising oxytocin, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising oxytocin wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the oxytocin.... Agent: Nixon Peabody LLP - Patent Group

20070087053 - Lozenge for treatment of dry mouth and related conditions: A composition and method for the treatment of dry mouth (xerostomia), comprising a sialogogic compound in combination with an effervescent organic acid-based buffering system.... Agent: Bingham, Mccutchen LLP

20070087055 - Directly compressible extended release alprazolam formulation: A directly compressible extended release pharmaceutical dosage form comprising alprazolam and at least two high viscosity polymers, wherein said first high viscosity polymer and said second high viscosity polymer are present in a ratio from about 4:1 to about 2:1.... Agent: Hedman & Costigan P.C.

20070087057 - Hydrogel-driven drug dosage form: A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least... Agent: Pfizer Inc.

20070087056 - Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility: Solid pharmaceutical formulation for a sustained pH-independent active ingredient release comprising at least one layer of one or more water-insoluble polymers, at least one layer of one or more pH-dependently water-soluble polymers and an active ingredient-containing core, having strong pH-dependent water solubility and comprises at least one osmagent.... Agent: Millen, White, Zelano & Branigan, P.C.

20070087058 - Osmotic implant with membrane and membrane retention means: An osmotic delivery system for controlled delivery of a beneficial agent includes an implantable capsule containing a beneficial agent and an osmotic engine that swells on contact with water, thereby causing the release of the beneficial agent over time. The osmotic delivery system has a membrane material that allows a... Agent: Trask Britt

20070087059 - Bioactive delivery matrix compositions and methods: Bioactive delivery matrix compositions and methods of making and using such compositions.... Agent: Mueting, Raasch & Gebhardt, P.A.

20070087060 - Ultrasound coupling medium for use in medical diagnostics: A composition of an ultrasound coupling medium is provided. The composition comprises at least 90% water, at least one preservative, and at least one base substance, wherein the composition is extensible into a film with a thickness of up to 1/10 mm, wherein the composition can withstand a pressure of... Agent: Speckman Law Group PLLC

20070087061 - Method and composition for creating and/or activating a platelet-rich gel by contact with a porous particulate material, for use in wound care, tissue adhesion, or as a matrix for delivery of therapeutic components: A composition, method, and use of microporous particles such as polysaccharide hemostat particle gels activates platelet rich plasma (PRP) or other platelet-containing substances. The composition may contain microporous polysaccharaide hemostats (MPH) mixed with platelet-rich plasma, platelet-poor plasma, blood, or the like. The method may contain mixing the MPH with platelet-rich... Agent: Mark A. Litman & Associates, P.A. York Business Center

20070087062 - Ginseng wine: The present application discloses a process for making ginseng wine.... Agent: Jhk Law

20070087063 - Medical composition for balancing bodily processes: Medical compositions and methods using same to nutritionally support balance of bodily processes are disclosed. A medical composition to nutritionally support balance of bodily processes involving S-adenosylmethionine is disclosed.... Agent: Mcdermott Will & Emery LLP

20070087064 - Composition for preventing and treating climacteric symptoms comprising the extract of sophorae fructus: The present invention relates to a composition for preventing and treating climacteric symptoms comprising the extract of Sophorae Fructus as an effective ingredient. Precisely, the present invention relates to the extract of Sophorae Fructus having an effect of preventing and treating climacteric symptoms, a composition comprising the extract and a... Agent: Buchanan, Ingersoll & Rooney PC

20070087065 - Soy products with reduced levels of sulfite, free radicals and methanethiol: Soy products or compositions are treated with a food grade iodate compound or a cystine compound to reduce levels of methanethiol, sulfites and sulfite free-radicals, sulfate free radicals and other free radicals generated from sulfite free radicals in the soy products or compositions by 1% to 95%.... Agent: Mcdermott Will & Emery LLP

20070087066 - Antifungal effects of morinda citrifolia: The present invention relates to antifungal and antibacterial activity of processed Morinda citrifolia products, as well as from various fractions of extracts from these processed products and the Morinda citrifolia L. plant, and related methods to determine mean inhibitory concentrations. In particular, the present invention relates to ethanol, methanol and... Agent: Kirton And Mcconkie

20070081941 - F-18 labeled amino acid analogs: R is (C1-C6)alkyl optionally substituted with thioether or ether oxygen atom when n=0, or a substituted aromatic or heteraromatic ring when n=1-6; and m=0 or 1; and X is a halogen atom. The invention further relates to precursor compounds for these analogues, to a method of preparing these analogues, to... Agent: Jeffrey S. Boone Mallinckrodt Inc.

20070081940 - Radioactive source materials formable into various shapes: The present invention provides an integral source material, the integral source material has at least one nuclide that is an integral source material having at least one nuclide that is activatable by exposure to radiation, the nuclide is a chemically bound constituent of a polymer of the integral source material,... Agent: Myers Bigel Sibley & Sajovec

20070081942 - Gene differentially expressed in breast and bladder cancer, and encoded polypeptides: The present invention is directed to antibodies or antigen binding fragments thereof that specifically bind to the cancer specific antigen, C35. This invention also relates to a polynucleotide encoding the antibody or antigen binding fragment thereof as well as vectors and host cells comprising the polynucleotide. The present invention further... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070081943 - Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism: The present invention is directed to a screening mechanism for identifying members of the general population at increased risk for alcoholism and premenstrual syndrome. The screening mechanisms may be used to measure the expression of the α4β2δ GABAA receptors, in order to identify members of the general population as having... Agent: Dilworth & Barrese, LLP

20070081944 - Iontophoresis apparatus and method for the diagnosis of tuberculosis: An iontophoresis device includes an active electrode assembly including an active electrode element and at least one active agent reservoir. Active agents include one or more polypeptides, or fusion polypeptides, having antigenic determinants derived from or related to M. tuberculosis antigens and suitable for detection of tuberculosis.... Agent: Seed Intellectual Property Law Group PLLC

20070081945 - Magnetic resonance imaging contrast agents: This invention relates to novel magnetic resonance imaging contrast agents, and methods of making and use thereof.... Agent: Fish & Richardson PC

20070081946 - Assembly of gas-filled microvesicle with active component for contrast imaging: Assembly comprising a gas-filled microvesicle and a structural entity which is capable to associate through an electrostatic interaction to the outer surface of said microvesicle (microvesicle associated component—MAC), thereby modifying the physico-chemical properties thereof. Said MAC comprises a targeting ligand a diagnostic agent or any combination thereof. Optionally a bioactive... Agent: Bracco Research Usa Inc.

20070081947 - Solid active ingredient formulation: The present invention relates to novel solid active substance formulations comprising solid active substances, dispersants, and polymers which together result in a fine-particle, predominantly amorphous mixture, to a process for the preparation thereof and to the use thereof for application of the contained bioactive active substances.... Agent: Norris, Mclaughlin & Marcus, P.A.

20070081948 - Dry powder composition comprising a benzodiazepine for pulmonary inhalation: Manufacture of Pharmaceutical Compositions The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically active material for pulmonary inhalation, the method comprising a jet milling process.... Agent: Davidson, Davidson & Kappel, LLC

20070081949 - Buccal drug delivery: A lozenge is provided that has stable pH and stable levels of active ingredient over time. It comprises a combination of (i) at least one gum and (ii) at least one non-crystallising sugar or non-crystallising sugar alcohol in a matrix designed for controlled buccal delivery of a drug. The lozenge... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070081950 - Solid oral tooth whitening confectionary composition: The present invention provides a solid, oral toolh whitening composition comprising a tooth whitening agent comprising calcium pyrophosphate present in an amount between 0.5% and 9% by weight of the composition, excluding any coating. In one embodiment, the composition of the invention comprises an additional tooth whitening agent... Agent: Greenblum & Bernstein, P.L.C

20070081951 - Prevention of dental plaque and dental calculus in animals: The present invention provides methods to improve the dental health of an animal, comprising inhibiting dental plaque and calculus on the teeth of a dental plaque- and calculus-forming animal, comprising contacting said teeth with a food product comprising an amount of an antimicrobial agent effective to inhibit dental plaque and... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070081952 - Composition for the treatment of bad breath: A composition suitable for treating bad breath and including a carrier material, at least one enzyme sulphite oxidase, an enzyme for breaking down the starch and/or cellulose present in the oral cavity to give glucose, an enzyme oxidoreductase, a source of halogen or pseudohalogen ions, and an enzyme peroxidase.... Agent: Dennison, Schultz & Macdonald

20070081953 - Surfactant mixtures for improving the deposition of active substances and for reducing the skin irritant action: A use of mixtures of surfactants which form multilamellar liquid-crystalline structures, where the surfactants are chosen from at least two of the following groups formed from isethionates, taurates, sarcosinates, acyl lactylates, acyl glutamates, fatty acid-protein condensates, PEG stearates, PEG distearates with an HLB value of less than 10, alkyl polyglycosides... Agent: Birch Stewart Kolasch & Birch

20070081954 - Dispersion of polymer particles, composition comprising it and cosmetic treatment method: The present patent application relates to novel dispersions of particles of a polymer which is stabilized at the surface, in a nonaqueous medium, in which dispersions the polymer exhibits a specific glass transition temperature. Another aspect of the present disclosure is a cosmetic or pharmaceutical composition comprising the said dispersion... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070081955 - Method and display for merchandising nail products: A blister pack comprised of a card having a product to be used in a stepwise process for grooming the nails blistered thereto wherein the card contains indicia noting the step of the stepwise nail grooming process the blistered product is to be used in; a retail display where nail... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070081956 - Admistration of c-glycoside compounds for depigmenting/whitening the skin: b

20070081957 - Deodorant and deodorizing article: A deodorant includes a powder of an amine salt of a phosphorus inorganic acid, the powder having an average particle diameter of 0.1 to 30 μm. The amine salt of a phosphorus inorganic acid is preferably an ammonium salt. Deodorant products including the deodorant such as an adhesive, a paint... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070081958 - Body care product containing porous silver particles: The invention relates to a body care product containing porous particles made of metal containing silver and having an average diameter size of between 1 and 100 μm.... Agent: Pearne & Gordon LLP

20070081959 - Cosmetic oligo-alpha-olefin containing compound: The disclosed invention relates to a cosmetic composition containing at least one branched oligo-α-olefin, characterized in that the side chains at one branch point at least are ethyl, propyl or longer branched alkyl chains, the branched oligo-α-olefin being obtainable by oligomerization of a) at least one branched α-olefin containing 5... Agent: Cognis Corporation Patent Department

20070081960 - Pharmaceutical compositions containing botulinum toxin: This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000... Agent: Allergan, Inc.

20070081963 - Composition for improving skin conditions comprising human growth hormone as an active ingredient: Disclosed herein is a skin condition-improving composition for topical application to the skin, comprising human growth hormone as an active ingredient, and a method for improving skin conditions using the same. The disclosed composition exhibits various skin conditioning effects, such as acne treatment, wrinkle improvement, dark spot removal, skin elasticity... Agent: The Rafferty Patent Law Firm

20070081961 - Extraction and use of collagen extracted from either a sea mammal or a bony fish: A process for a cell culture wherein the cells are grown on a substrate, the improvement comprising the step of growing the cells on collagen substrate with the collagen having been extracted from an animal selected from the group consisting of a marine mamal and a bony fish. Preferred embodiments... Agent: Dla Piper US LLP Attn: Patent Group

20070081962 - Novel delivery of immune response modifiers for removal of chronic tattoos: The present invention contemplates methods and compositions for removing a tattoo. In one aspect, the present invention contemplates the use of a macrophage cell disrupter, optionally with an IRM for removing a tattoo. Both the IRM and the macrophage cell disrupter may be admixed with an adhesive. In one aspect... Agent: Wilson Sonsini Goodrich & Rosati

20070081964 - Use of polymers based on n-vinyl caprolactam in hair cosmetics: Use of polymers of 30-65% by weight of N-vinylcaprolactam, 35-65% by weight of a monomer mixture of N-vinylimidazole and vinylpyrrolidone, where the weight ratio of N-vinylimidazole to vinylpyrrolidone is between 0.085 and 0.30, 0-15% by weight of a nitrogen-containing quaternizable monomer (A), which is different from N-vinylimidazole, where the sum... Agent: Connolly Bove Lodge & Hutz, LLP

20070081965 - Hair conditioning compositions: Rinse-off hair conditioning compositions with improved opacity and reflectivity are disclosed which comprise, in addition to water, C16 to C22 alkyl trimethylammonium salt, C16 to C22 dialkoylethyl dimethylammonium salt, C12 to C22 fatty material and alkali metal halide.... Agent: Unilever Intellectual Property Group

20070081966 - Use of alcohols ethoxylated by alpha-hydroxycarboxylic acid esters: The disclosed invention relates to the use of alcohols ethoxylated by hydroxy-carboxylic acid esters as moisture dispensers for the skin in cosmetics, especially in preparations containing a surfactant.... Agent: Cognis Corporation Patent Department

20070081968 - Agent for inducing hair growth containing extracts of saw palmetto and swertia: The present invention consists in a composition comprising a mixture of extracts of saw palmetto and swertia, of derivatives thereof and of active components being part of said extracts. The composition may comprise additional agents and/or extracts, for example, irritating agents, extracts for hair invigoration, hair nourishment agents, antidandruff anti-proliferative... Agent: Alston & Bird LLP

20070081967 - Revitalizing hair follicles with total parenteral nutrition or hyperalimentation for maximum hair growth: The present invention relates to composition and method for revitalizing hair growth, rebuilding and restoring the natural integrity of the hair follicles wherein a first treatment formulation containing active ingredients comprising of vinpocetine, niacin, proanthocyanidins, azelaic acid, isopropyl alcohol, propylene glycol, and water is applied to the scalp as a... Agent: Jeong Han Oh

20070081969 - Dissemination apparatus: An apparatus for disseminating volatile liquid such as fragrance or insecticide into an atmosphere from a reservoir, the transfer to atmosphere being at least partially achieved by means of a transfer member having external capillary channels. The volatile liquid is one in which at least 30% by weight of the... Agent: Norris, Mclaughlin & Marcus

20070081973 - Cytokine polypeptides: This invention relates to IMX129840 cytokines, including new mammalian cytokine polypeptides; to methods of making such polypeptides; to methods of using them to treat conditions and diseases involving proliferation and/or differentiation of cells from pluripotent stem cell precursors; and to methods of identifying compounds that alter IMX129840 cytokine polypeptide activities.... Agent: Immunex Corporation Law Department

20070081970 - G-csf-containing substance for fibroblast recruitment and g-csf-contianing therapeutic agent for wound healing: The object of the present invention is to achieve simple recruitment of fibroblasts into wounded tissues and engraftment of the fibroblasts in the wounded tissues, thereby healing the wounds without requiring fibroblast transplantation. Upon G-CSF administration, fibroblasts migrate into myocardial infarct lesions and prevent a reduction in cardiac function, thus... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070081972 - Polymer-based delivery system for immunotherapy of cancer: The present invention relates to the treatment of cancer using a polymer-based delivery system to provide a plurality of tumor cell antigens to a immunocompetent subject in conjunction with an immunodulatory substance.... Agent: Fulbright & Jaworski L.L.P.

20070081971 - Stable pharmaceutical compostion comprising granulocyte-colony stimulating factor: The present invention provides a new stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF).... Agent: Novartis Corporate Intellectual Property

20070081974 - Antibody targeting osteoclast-associated protein: The present invention relates to a method of detecting metabolic bone disorders using a gene expressed at a high level in osteoclasts, a method of screening for a compound effective for treatment and/or prevention of metabolic bone disorders, and a pharmaceutical composition for treatment and/or prevention of metabolic bone disorders.... Agent: Ip - Seattle Dorsey & Whitney LLP

20070081975 - Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis: The present invention provides a method of treatment or prevention of sepsis and other diseases characteristic to the Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock, and sepsis related to cardiac dysfunction.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070081976 - Bioconjugates comprising sulfated polysaccharides and their uses: The present invention provides bioconjugates comprising a sulfated polysaccharide such as alginate sulfate and hyaluronan sulfate and at least one bioactive polypeptide capable of binding a sulfate group of said sulfated polysaccharide. The bioactive polypeptide can be a heparin-binding polypeptide and/or a positively-charged polypeptide. Also, provided are delivery systems and... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070081978 - Adeno-associated virus-mediated survivin mutants and methods related thereto: This invention provides two novel vectors, a vector comprising a rAAV-type 2 plasmid encoding mutant survivin (Cys84Ala), and a vector comprising a rAAV-type 2 plasmid encoding eGFP. This invention also provides compositions comprising the above vectors. This invention provides a method for inducing apoptosis in a cell comprising introducing into... Agent: Cooper & Dunham, LLP

20070081977 - Device for transdermal administration of active substances: A device for transdermal administration of active substances, comprising a backing layer and an active substance-containing reservoir connected to the backing layer. The skin-facing contact surface of the device has a plurality of microprotrusions which are suitable for penetrating the skin and which are equipped with structures that make extracting... Agent: D. Peter Hochberg Co. L.p.a.

20070081983 - Isolation of smooth muscle cells and tissue-engineered vasculature containing the isolated cells: The present invention is directed to a method of isolating smooth muscle cells or progenitors thereof from a mixed population of cells. A preparation of isolated smooth muscle cells or progenitors thereof, where the smooth muscle cells or progenitors thereof constitute at least 90% of the preparation, is also disclosed.... Agent: Nixon Peabody LLP - Patent Group

20070081982 - Multiple rnai expression cassettes for simultaneous delivery of rnai agents related to heterozygotic expression patterns: The present invention provides compositions and methods suitable for expressing y-x multiple-RNAi agents against an allele or alleles of interest in cells, tissues or organs of interest in vitro and in vivo so as to treat diseases.... Agent: Patterson & Sheridan, L.L.P.

20070081981 - P18 in stem cell manipulations: A method to increase self-renewal of an undifferentiaded human stem cell culture or cell line, by reducing or eliminating the presence of the protein “p18”.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070081980 - Culture cells from pancreatic islets: A cell composition of endocrine progenitor cells derived from mammalian pancreatic islet cells that can be trans-planted planted into a diabetic patient such t the cells of the cell composition differentiates into functioning insulin-producing beta cells.... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20070081979 - Multi-functional chimeric hematopoietic receptor agonists: Disclosed are novel multi-functional chimeric hematopoietic receptor agonist proteins, DNAs which encode the multi-functional chimeric hematopoietic receptor agonist proteins, methods of making the multi-functional chimeric hematopoietic receptor agonist proteins and methods of using the multi-functional chimeric hematopoietic receptor agonist proteins.... Agent: Carol M. Nielsen Winstead Sechrest & Minick, P.C.

20070081984 - Compositions and methods for treating hypophosphatasia: The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP... Agent: Saint Louis University Office Of Innovation And Intellectual Property

20070081986 - Beta-glucuronidase with an attached short peptide of acidic amino acids: Disclosed are a fusion protein comprising enzyme β-glucuronidase and short peptide consisting 4-15 acidic amino acids attached to the enzyme on its N-terminal side, pharmaceutical composition containing the fusion protein, and a method for treatment of type VII mucopolysaccharidosis using the fusion protein. Compared with the native enzyme, the fusion... Agent: Millen, White, Zelano & Branigan, P.C.

20070081985 - Lysozyme fortified milk and milk products: Milk and/or yogurt fortified with lysozyme for augmentation of the immune system and aid the immune compromised.... Agent: Norris, Mclaughlin & Marcus P.A.

20070081988 - Enzyme inhibitors of pai-1: The invention provides a method for the treatment of a subject suffering from a cardiovascular disease using a therapeutically effective amount of at least one enzyme that is capable of inhibiting PAI-1 activity. The invention also provides a method of decreasing the risk of the occurrence of a cardiovascular disease... Agent: Foley And Lardner LLP Suite 500

20070081987 - Novel peptides and compositions which modulate apoptosis: The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the “GD domain,” which is essential both... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070081989 - Treatment of b cell diseases using anti-germline antibody binding agents: Methods for reducing the number of pathologic antibody producing B cells in a patient suffering from an autoimmune disease by administration of an anti-germline antibody are described. Methods for removing pathologic antibodies and B cells and plasma cells producing pathologic antibodies from the body of a patient suffering from autoimmune... Agent: Cynthia Ruth Moore

20070081991 - Compositions and methods for modulation of immune responses: The present invention relates to a novel mechanism for modulation of immune response. More closely, the present invention relates to modulation of CD94/NKG2 receptor yfunction by HLA-E+bound peptides causing either inhibition or absence of inhibition of said receptors. In a preferred embodiment the invention relates to HLA-E binding hsp (heat... Agent: Perkins Coie LLP

20070081990 - Regulation of expression of high-affinity immunoglobulin e (ige) receptor beta-chain: The present invention provides a polynucleotide comprising all or a part of the nucleotide sequence identified as SEQ ID NO:1 that regulates transcription of the human high-affinity IgE receptor (FcεRl) β-chain gene, and a method for regulating transcription of the FcεRl β-chain gene which comprises the step of promoting binding... Agent: Morgan Lewis & Bockius LLP

20070081992 - Fusion proteins for blood-brain barrier delivery: The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments the... Agent: Wilson Sonsini Goodrich & Rosati

20070081994 - Chimeric heteromultimer adhesins: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed... Agent: Merchant & Gould PC

20070081993 - Pharmaceutical composition comprising a bispecific antibody for epcam: The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3... Agent: Foley And Lardner LLP Suite 500

20070081996 - Method of treating depression using a tnfalpha antibody: The invention describes methods of treating depression comprising administering a TNFα antibody, such as a human TNFα antibody.... Agent: Lahive & Cockfield, LLP

20070081995 - Methods and compositions for targeting ifnar2: Anti-IFNAR2 monoclonal antibodies, and methods for using the antibodies, are provided.... Agent: Genentech, Inc.

20070081998 - Anti-addl monoclonal antibody and use thereof: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also... Agent: Licata & Tyrrell P.C.

20070081999 - Antithrombotic von willebrand factor (vwf) collagen bridging blockers: The present invention clearly demonstrates that vWF-collagen interaction plays an important role in acute platelet-dependent arterial thrombus formation and that blockade of vWF-collagen interaction can induce complete abolition of thrombus formation in the injured and stenosed baboon femoral arteries. Accordingly, a blocker of vWF-collagen can be used as a compound... Agent: Clark & Elbing LLP

20070081997 - Diagnostics and therapeutics for diseases associated with kallikrein 9 (klk9): The invention provides a human KLK9 which is associated with the hematological diseases, cardiovascular diseases, neurological diseases, metabolic diseases, urological diseases, cancer disorders, inflammation disorders, dermatological diseases and gastroenterological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular... Agent: Banner & Witcoff

20070082000 - D1-1 nucleic acids, polypeptides and related methods: The disclosure provides, among other things, novel angiogenesis-related nucleic acids, polypeptides and methods of use.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070082001 - Novel engineered superantigen for human therapy: The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.... Agent: Fulbright & Jaworski L.L.P. Fulbright Tower

20070082002 - Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture and therapeutic use thereof: A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro primary of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20070082003 - Method for selecting and producing vaccine components and vaccines based thereon: The invention relates to the field of biology, more specifically to the field of immunology and microbiology. The invention further relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify,... Agent: Hoffmann & Baron, LLP

20070082004 - Method for removing a proteinaceous component from a liquid-phase surfactant preparation: The present invention provides a method for removing a proteinaceous component from a liquid-phase surfactant preparation comprising (a) providing a liquid-phase surfactant preparation containing a proteinaceous component; (b) adding a complexing agent to the preparation of step (a) and allowing the complexing agent to form a complex with the surfactant;... Agent: Synnestvedt & Lechner, LLP

20070082006 - Novel immunogenic compositions for the prevention and treatment of meningococcal disease: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of... Agent: Hunton & Williams LLP Intellectual Property Department

20070082007 - Novel immunogenic compositions for the prevention and treatment of meningococcal disease: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of... Agent: Hunton & Williams LLP Intellectual Property Department

20070082005 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070082008 - Feed formulation for terrestrial and aquatic animals: The use of macroalgal, microalgal, and fungally-derived materials provide, in combination with higher-plant derived materials, complete feeds for animal husbandry. The products and methods of the invention provide nutritional feed formulations, that reduce or eliminate the need for animal-derived materials. The feeds are useful for terrestrial or aquatic animals, and... Agent: Duane Morris, LLPIPDepartment

20070082009 - Methods of preparation of live attenuated bacterial vaccine by alteration of dna adenine methylase (dam) activity in those bacteria: Live attenuated bacteria vaccines are provided. Also provided are methods by which such vaccines can be obtained, including: a method by which a copy of the dam gene from a pathogenic bacteria is cloned into a plasmid capable of replication in the same bacteria species such that it is overexpressed... Agent: Dla Piper US LLP Attn: Patent Group

20070082010 - Urogenital or anorectal transmucosal vaccine delivery system: The invention is directed to a suppository based vaccine delivery system for immunizing against urogenital and anorectally transmitted infectious disease in humans and animals and a method for treating the same. More particularly, this invention is directed to a suppository based vaccine delivery system for the prophylaxis against or treatment... Agent: Davidson, Davidson & Kappel, LLC

20070082011 - Recombinant proteins from filoviruses and their use: Filovirus subunit protein immunogens are produced using a recombinant expression system and combined with one or more adjuvants in immunogenic formulations. The subunit proteins include GP95, GP-FL, VP40, VP24, and NP derived from Ebola Virus and Marburg Virus. Adjuvants include saponins, emulsions, alum, and dipeptidyl peptidase inhibitors. The disclosed immunogenic... Agent: Paradise Patent Services, Inc. Attn: George Darby

20070082012 - Vaccines and methods to treat canine influenza: The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine... Agent: Pharmacia & Upjohn

20070082013 - Use of botulinum toxin for producing drug for preventing or treating final phase of lung troubles: The invention relates to the use of botulinum toxin for producing a drug for preventing or treating the final phase of lung troubles.... Agent: Hunton & Williams LLP Intellectual Property Department

20070082014 - Injectable vaccines against multiple meningococcal serogroups: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 μg meningococcal saccharide per dose, and/or (ii) the composition further... Agent: Novartis Vaccines And Diagnostics Inc.

20070082015 - Cloning and expression of outer membrane protein c of salmonella typhi ty2 and conjugation of the purified insoluble protein to vi-polysaccharide for use as a vaccine for typhoid fever: The invention relates to a novel carrier protein for use as a vaccine comprising the outer membrane protein C (OmpC) of Salmonella typhi Ty2 for conjugation with VI polysaccharide.... Agent: The Webb Law Firm, P.C.

20070082017 - Lipid compositions and methods of use: The present invention relates to a composition comprising: a C12 to C24 branched or unbranched hydrocarbon; a mid-chain triglyceride; a C26 to C36 branched or unbranched hydrocarbon; a cholesteryl ester; an ester of a C10 to C24 fatty acid and a C10 to C20 alcohol; an ester of a C10... Agent: Wilson Sonsini Goodrich & Rosati, P.C. Attn: Jeffery W. Guise, Esq

20070082016 - Microemulsion preconcentrate comprising a renin inhibitor: The present invention relates to pharmaceutical compositions for oral administration comprising a δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide renin inhibitors as the active ingredient. In particular, the present invention relates to galenic formulations in the form of microemulsion preconcentrates comprising the active ingredient and at least one absorption enhancing excipient which preconcentrates provide... Agent: Novartis Corporate Intellectual Property

20070082018 - Stabilized antimicrobial compositions and related methods of preparation: Antimicrobial compositions and related methods as can be used to enhance stability and/or maintain antimicrobial activity.... Agent: Reinhart Boerner Van Deuren S.c. Attn: Linda Kasulke, Docket Coordinator

20070082020 - Blood clot filter having coating: The present invention is directed to a blood clot filter for implantation in a patient comprising a blood clot filter having a coating comprising one or more pharmaceutically active compounds.... Agent: Louis A. Piccone

20070082021 - Coated vaso-occlusion device: Compositions and methods for occluding a vessel in a subject are provided in which a vaso-occlusion device includes an occluding element having a polymeric material containing a plurality of holes at least partially filled with one or more bioactive agents, the vaso-occlusion device configured to occlude a vessel in the... Agent: Brinks Hofer Gilson & Lione

20070082022 - Latent reactive blood compatible agents: A reagent and related method for use in passivating a biomaterial surface, the reagent including a latent reactive group and a bifunctional aliphatic acid (e.g., fatty acid), in combination with a spacer group linking the latent reactive group to the aliphatic acid in a manner that preserves the desired function... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20070082019 - Photocrosslinked hydrogel surface coatings: A hydrogel layer is applied to a substrate advantageously when the layer is formed in situ, using a polymeric or copolymeric precursor that includes, respectively, monomer subunits that have a photocrosslinkable functionality and monomer subunits that have a chemically selective functionality for binding a biomolecular analyte, such as a protein.... Agent: Ciphergen C/o Foley & Lardner LLP

20070082023 - Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan: Supple tissue dressing assemblies are formed from hydrophilic polymer sponge structures, such as chitosan. The supple tissue dressing assemblies are characterized by suppleness or multi-dimensional flexibility. The assemblies can be flexed, bent, folded, twisted, and even rolled upon itself before and during use, without creasing, cracking, fracturing, otherwise compromising the... Agent: Ryan Kromholz & Manion, S.c.

20070082028 - Compositions and methods for inducing satiety and reducing caloric intake: Compositions and methods for inducing statiety and for reducing caloric intake having at least soluble anionic fiber and at least one soluble cation. The compositions may be solid, fluid, or mixtures thereof.... Agent: Philip S. Johnson Johnson & Johnson

20070082026 - Compositions and methods for reducing food intake and controlling weight: A formed food or other ingestible composition having at least one soluble anionic fiber and at least one multivalent cation wherein the combination of fiber and cation increases viscosity of digesta. Methods of weight management including inducing satiety, reducing caloric intake, weight loss and improving weight loss, using the formed... Agent: Philip S. Johnson Johnson & Johnson

20070082027 - Compositions and methods for reducing food intake and controlling weight: An ingestible composition to increase viscosity imparted to the digesta in an intestine that includes a soluble anionic fiber and a protected cation. The protected cation may be coated with an enteric coating, a lipid coating, or a sustained release coating.... Agent: Philip S. Johnson Johnson & Johnson

20070082029 - Fiber satiety compositions: Ingestible compositions that include one or more anionic soluble fibers are provided herein. An ingestible composition can be in solid or liquid form. In certain cases, a solid ingestible composition includes an extruded food product, such as a crispy, that includes one or more anionic soluble fibers. Liquid ingestible compositions... Agent: Fish & Richardson P.C.

20070082030 - Fiber satiety compositions: Ingestible compositions that include one or more anionic soluble fibers are provided herein. An ingestible composition can be in solid or liquid form. In certain cases, a solid ingestible composition includes an extruded food product, such as a crispy, that includes one or more anionic soluble fibers. Liquid ingestible compositions... Agent: Fish & Richardson P.C.

20070082025 - Methods for achieving and maintaining weight loss: Methods for achieving weight loss goals and maintaining weight loss including selecting an appropriate weight loss program and identifying a weight loss goal, followed by participating in the weight loss program until the weight loss goal is achieved; then ending the weight loss program participation; and consuming an ingestible composition... Agent: Philip S. Johnson Johnson & Johnson

20070082024 - Tyrosinase activity inhibitor and ameliorant for facial blood flow: A tyrosinase activity inhibitor and an ameliorant for facial blood flow that are excellent in terms of safety, and medicinal compositions, food compositions, and cosmetic preparations that contain the inhibitor and the ameliorant as active ingredients are provided. A tyrosinase activity inhibitor and an ameliorant for facial blood flow that... Agent: Posz Law Group, PLC

20070082031 - L-lysine-containing feed additives: The invention relates to relatively light and thermally stable granulated, fermentation-broth-based animal feed additives having a high content of L-lysine and to low-loss methods for their production from broths obtained by fermentation.... Agent: Smith, Gambrell & Russell

20070082035 - Anti-infective hygiene products based on cellulose acetate phthalate: Methods for maintaining a low vaginal pH, preventing the propagation of toxic shock syndrome toxin 1 production during menstruation, preventing the shedding and dissemination of a herpesvirus and treating herpes lesions comprising administering to a human a formulation comprising a pharmaceutically effective amount of an insoluble micronized form of cellulose... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070082034 - Dual-sided cleansing wipes for medical equipment: A two sided cleansing wipe has a first side treated with a cleaner and a second side treated with a disinfectant. The wipe is used to first apply the cleaner to the surface of an object and thereafter apply a disinfectant. The first side may contain a color indicator to... Agent: Andrus, Sceales, Starke & Sawall, LLP

20070082032 - Skin care pad: The invention relates to a skin care pad comprising exfoliating elements (4) which are distributed between at least one first fibrous layer (2) and a second fibrous layer (6), said second layer having a lower basis weight than the first fibrous layer. In this way, the inventive pad can be... Agent: Patent Group Ga030-43 Georgia-pacific LLC

20070082033 - Substrate containing lipids: Cleansing article of a textile that is impregnated with a preparation containing a) one or more anionic surfactants in a total concentration of from 1 to 30% ,by weight and b) one or more lipids liquid or viscous at room temperature in a total concentration of at least 8% by... Agent: Greenblum & Bernstein, P.L.C

20070082036 - Wound care dressing and method using same: A wound care dressing is disclosed. The wound care dressing comprises a water-soluble nonwoven blanket in combination with a planar, non-water soluble wound care composition.... Agent: Dale F. Regelman

20070082039 - Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids: The present invention provides a novel approach for the preparation of fatty alcohol esters of α-hydroxy carboxylic acids. The present invention also provides a novel topical gel for the transdermal delivery of steroids using the fatty alcohol esters as permeation enhancers.... Agent: Mark J. Pandiscio Pandiscio & Pandiscio, P.C.

20070082041 - Topical delivery of codrugs: The present invention provides pharmaceutical compositions for topical delivery comprising a suitable carrier and a codrug capable of penetrating, or being transported across, the dermis. The codrug according to the invention comprises a first constituent moiety linked to a second constituent moiety, wherein the second constituent moiety is the same... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070082040 - Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides: The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of a peptide or polypeptide that generates hydrophilic micro-channels, and a patch comprising dried therapeutically peptide or polypeptide. Particularly, the system of... Agent: Winston & Strawn LLP Patent Department

20070082038 - Transdermal nicotine salt delivery system: A transdermal nicotine salt delivery system to an individual. The system has a high nicotine salt loading to effect therapeutic flux rate. Acrylate polymeric drug reservoir with the high nicotine salt dissolved therein provides desirable adhesive characteristics and effective transdermal therapeutic properties.... Agent: Philip S. Johnson Johnson & Johnson

20070082037 - Transdermal preparations and method for relieving side effects in pergolide therapy: It is intended to provide pergolide-containing transdermal preparations having reducreduced side effects and exerting sufficient therapeutic effects. Namely, a pergolide-containing transdermal preparation which is capable of achieving a plasma AUC ratio of pergolide or the like to at least one pergolide metabolite of 1:0.5 to 1:5; and/or transdermal preparation containing... Agent: Licata & Tyrrell P.C.

20070082043 - Liposomal vaccine: The invention provides liposomal vehicles for encapsulating relatively high levels of water-soluble substances including immunogens directed against gastrin and gonadotropin releasing hormone. The liposome encapsulating large amounts of immunogens can be injected parentally to induce effective immune responses without exhibiting significant adverse tissue reactogenicity.... Agent: White & Case LLP Patent Department

20070082042 - Multiple-layered liposome and preparation method thereof: Disclosed are multilayered liposomes for transdermal absorption and a method of preparing the liposomes. The multilayered liposomes are prepared using a mixture of oil-phase components comprising squalane, sterols, ceramides, neutral lipids or oils, fatty acids and lecithins, is 200 to 5000 nm in particle size, and is capable of entrapping... Agent: Anderson, Kill & Olick, P.C.

20070082045 - Seamless capsule manufacturing method, seamless capsule manufacturing device and seamless capsule: A seamless capsule manufacturing device comprises a multiple nozzle 7 for ejecting liquid drops into hardening liquid 10 and a flow passage tube 11 for containing hardening liquid 10. The flow passage tube 11 has a deformation section 28 that includes an inlet part 25 and a formation tube part... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070082044 - Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene: The methods of the invention can be used to protect against lymphocyte DNA damage and free-radical associated disorders in a subject. The methods of the present invention can be used to increase the antioxidant capacity in both the aqueous and lipid compartments, decrease DNA oxidation, decrease lipid peroxidation, and increase... Agent: Nutter Mcclennen & Fish LLP

20070082046 - Enteric valproic acid: An enteric valproic acid soft gelatin capsule, in which the enteric polymer is a component of the capsule shell rather than a coating, has been developed. The fill material comprises valproic acid or divalproex sodium and, optionally, one or more pharmaceutically acceptable excipients such as corn oil. The capsule shell... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070082048 - Sleep aid formulations: Orally dissolvable dosage forms comprising sleep aids such as benodiazepines are described. The dosage forms may be in the form of tablets or strips. In certain embodiments, the dosage forms may comprise particles, granules, microgranules, or crystals, and a matrix. The particles, granules or microgranules comprise a combination of immediate-release... Agent: Patrick J. Halloran, Ph.d., J.d.

20070082047 - Solid preparation: A chewable tablet comprising a group which contains an acid-labile active ingredient and at least one basic substance selected from alkaline earth metal carbonate, metal oxide and metal hydroxide, and a group which does not contain an acid-labile active ingredient and contains at least one ingredient selected from alkaline earth... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070082049 - Extended release venlafaxine tablet formulation: An extended release formulation for administration of venlafaxine in an oral tablet dosage form. The formulation preferably features a core, over which an outer coating is layered. The core preferably contains venlafaxine, a filler, and a water soluble cellulosic polymer, optionally and more preferably with a water insoluble cellulosic polymer.... Agent: Martin Moynihan Prtsi Inc

20070082050 - Modified release formulations of antihypertensive drugs: Modified or extended release formulations containing propanolol compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved propanolol formulations such as INDERAL LA®.... Agent: Thorpe North & Western, LLP.

20070082051 - Modified release formulations of antihypertensive drugs: Modified or extended release formulations containing propanolol compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved propanolol formulations such as INDERAL LA®.... Agent: Thorpe North & Western, LLP.

20070082053 - Solid dispersions of opioid antagonists: Solid dispersions of stable, amorphous opioid antagonists, particularly [[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]acetic acid, with improved water solubility and bioavailability are disclosed. Also disclosed are methods of preventing or treating a side effect associated with an opioid. In addition, methods of treating or preventing pain, ileus, and opioid bowel dysfunction are disclosed.... Agent: Woodcock Washburn LLP

20070082052 - Tympanic membrane repair constructs: The invention features methods of making hydrogel constructs that can be used to repair perforations in tympanic membranes, the hydrogel constructs themselves, and methods of repair.... Agent: Fish & Richardson PC

20070082054 - Particle size reduction of bioactive compounds: The invention provides a method for reducing the average size of biologically active compound particles or agglomerates suspended in a fluid by flowing one or more times said fluid having biologically active compound particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of... Agent: Clark & Elbing LLP

20070082055 - Stable micronized candesartan cilexetil and methods for preparing thereof: The invention encompasses sable candesartan cilexetil of fine particle size, wherein desethyl-candesartan (desethyl-CNS) within the stable candesartan cilexetil does not increase to more than about 0.1% w/w by HPLC relative to the initial amount of candesartan cilexetil, when the stable candesartan cilexetil is maintained at a temperature of about 55°... Agent: Kenyon & Kenyon LLP

20070082056 - Antibiotic peptide product: An antibiotic peptide is made by hydrolyzing milk protein. The hydrolysis is performed with a fungal protease in a single step at a protein concentration of 21 to 35 wt % to a DH of at least about 12%. The resulting antibiotic peptide has at least a log 2 kill... Agent: Richard D. Fuerle

20070082058 - Composition for repair of defects in osseous tissues: Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.... Agent: Baker & Mckenzie LLP

20070082057 - Compositions for repair of defects in osseous tissues, and methods of making the same: Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues, and methods for making the same. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.... Agent: Baker & Mckenzie LLP

20070082059 - Cross-linked collagenous biomaterial: A method or producing a cross-linked collagenous biomaterial includes the step of providing a collagenous biomaterial and irradiating the collagenous biomaterial with gamma radiation at a dose of between about 20 and 160 kGy to produce the cross-linked collagenous biomaterial. The collagenous biomaterial is provided in the form of a... Agent: D. Peter Hochberg Co. L.p.a.

20070082060 - Graft materials containing bioactive substances, and methods for their manufacture: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibrob-last Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070082061 - Reduction of saltiness with sweeteners: The present invention provides compositions for bowel cleansing that have improved palatability through the inclusion of a sweetener, such as a chlorinated sucrose isomer. The invention also provides methods of reducing the saltiness of an orally consumed substance, including phosphate salt and PEG/salt bowel cleansers, through the use of a... Agent: Evan Law Group LLC

20070082062 - Calcium phosphate-based materials containing zinc, magnesium, fluoride and carbonate: Compositions useful in the prevention and treatment of osteoporosis and for bone and fracture repair. Slow-releasing calcium phosphate-based materials are disclosed, incorporating Mg, Zn, F and carbonate, which will promote bone formation and inhibit bone resorption and thus be agents for the cited uses.... Agent: Klauber & Jackson

20070082064 - Nutritional or dietary supplement for the treatment of macular degeneration: A nutritional or dietary supplement composition that promotes retinal health through the prevention and/or treatment of visual acuity loss by reducing the risk of developing age-related macular degeneration in persons with early age-related macular degeneration. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, micronutrients and... Agent: Dilworth & Barrese, LLP

20070082063 - Risk assessment and correction of membrane damage of the upper gi tract: The present invention is directed to a variety of embodiments. For example, in at least one embodiment the invention is directed to formulations and methods for diagnosis of risk and for treatment to reduce this risk of upper gastrointestinal bleeding from erosions and ulcers. The compositions contain arachidonic acid, such... Agent: Vidas, Arrett & Steinkraus, P.A.

20070082065 - Therapeutic composition for the treatment of dry eye syndrome: A composition and method for treating dry-eye syndrome and symptoms of vitreous opacities in a host comprising the oral administration of a composition which contains a pharmacologically effective amount of essential fatty acids, polar phospholipids, vitamins, minerals and dietary supplements.... Agent: Dilworth & Barrese, LLP

20070082066 - Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity: Zeaxanthin, a dietary carotenoid that occurs in very small quantities in corn, spinach, and other dietary sources, can reduce light hyper-sensitivity and various related conditions (such as migraine or other recurrent headaches) in people who suffer from it. Preferred dosages range from about 10 to about 100 mg per day,... Agent: Jenkens & Gilchrist, P.C.

20070082067 - Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5: Novel triazole compounds represented by Formula (1): (where A, A1, A2, A3, A4, A5, B, R11, W, X, Y and Z are as defined herein) in which the triazole is substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of... Agent: Merck And Co., Inc

20070082068 - Il-8 production promoters and use thereof: An object of the present invention is to provide IL-8 production promoters derived from safe food materials and to provide immunostimulants or preventive or treating agents of infectious disease comprising the IL-8 production promoter. The present inventors have found that a composition comprising, as an active ingredient, at least one... Agent: Brinks Hofer Gilson & Lione

20070082069 - Process for preparation of labisia pumila extract: The present invention relates to a process for the preparation of Labisia pumila extract from Labisia pumila plant material and to obtain an optimized and reproducible chemical profile by high performance liquid chromatography.... Agent: Wolf Greenfield & Sacks, PC

20070082070 - Treating skin disorders: This document relates to methods and materials involved in treating skin disorders. For example, methods and materials for using an alpha adrenergic receptor agonist (e.g., midodrine) to treat mammals having a skin disorder are provided.... Agent: Fish & Richardson P.C.

20070082071 - Composition for controlling the respiratory effects of inhaled pollutants & allergens: An anti-inflammatory composition for application to the nasal mucosa includes a combination of essential oils. The composition is intended to help prevent and/or alleviate the effects of exposure caused by the inhalation of pollutants and allergens. Preferred embodiments of the composition include jojoba oil, rosemary oil, any of a variety... Agent: Robert M. Downey, P.A.

20070082072 - Herbal composition for treating cancer: The present invention relates to an herbal composition that provides anti-cancer effects, especially for breast cancer.... Agent: Wpat, PC Intellectual Property Attorneys

20070082073 - Catechin adjuvants: A combination cancer therapy based upon catechins, the major biologically active polyphenol in plant products, including green tea extract, and one or more chemotherapeutic agents. A common complication of cancer chemotherapy is neutropenia, and in spite of advances in its prophylactic management is a major cause of risk for the... Agent: Smith Hopen, Pa

20070082074 - Anti-inflammatory substances extracted from echinacea: An Echinacea composition containing the immunosuppressive components of an Echinacea extract but not the immunostimulatory components is disclosed. A process for isolating Echinacea immunosuppressive components by extraction with lipophilic compounds is also disclosed. The Echinacea composition can be used for treatment of colds, flu, and other upper respiratory tract infections,... Agent: Myers Bigel Sibley & Sajovec

20070082075 - Traditional chinese medicine preparation for treatment of tumor and method of making and using same: The invention provides a traditional chinese medicine and its' method of making for anti-tumor. The Traditional Chinese Medicine preparation is composed of following materials (by weight portion):SemenHydnocarpil, Momordicae Semen 0.8-1.4, Squama Manitis 0.5-1.1, Radix et Rhizoma Rhei 0.8-1.3, Radix Glycyrrhizae 1-1.5. The invented preparation possesses good curative effect and low... Agent: Rabin & Berdo, PC

20070082076 - Glutathione and coffee suppository: A composition containing coffee extract and glutathione in the form of a suppository.... Agent: Spencer Feldman

20070082077 - Inhibitor of glucose absorption and method for producing the same: This invention provides an inhibitor of glucose absorption and a method for producing the same. Such inhibitor of glucose absorption comprises, as an active ingredient, an acerola-derived substance capable of inhibiting glucose absorption.... Agent: Sughrue Mion, PLLC

20070077195 - \"n and/or nalpha derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [m(oh2)3 (co)3]+ by fac coordination\": The present invention relates to novel histidine derivatives that can be used for the labeling of biomolecules with radioactive metal tricarbonyls. The new derivatives have a histidine that is derivatized at the Nε and at least protected at the Nα and optionally at the Nδ; or derivatized at the Nα... Agent: Jeffrey S Boone Mallinckrodt Inc

20070077197 - Metal complexes derivatized with folate for use in diagnostic and therapeutic applications: Diagnostic and therapeutic compositions in the form of complexes for enhancing transmembrane transport of a diagnostic or therapeutic agent and methods for their use. The complexes contain the α, γ, or bis isomers of folate receptor-binding analogs of folate, a metal chelated by a ligand, and in one embodiment, a... Agent: Kramer Levin Naftalis & Frankel LLP

20070077198 - Method for preparing radiolabeled thymidine having low chromophoric byproducts: The invention is a method and related precursor for preparing 18F-FLT. The precursor has a butoxycarbonyl protecting group at the 5′-position that results in low amounts of chromophoric byproducts being formed during deprotection. The method for preparing 18F-FLT is efficient and makes the final purification step less complicated.... Agent: Siemens Corporation Intellectual Property Department

20070077196 - Radiolabeled thymidine solid-phase extraction purification method: A method and an apparatus for the manufacture of 3′-deoxy-3′-[18F]Fluorothymidine are disclosed. A fluorothymidine precursor, a reaction solvent for the fluorothymidine precursor, a source of [18F] ions, and dilution water are combined to form a reaction mixture including a radiolabeled thymidine product, [18F] ions, and residual reaction impurities. The reaction... Agent: Quarles & Brady LLP

20070077199 - Humanized collagen antibodies and related methods: The invention provides an antibody, or functional fragment thereof, a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the antibody or functional fragment thereof has specific... Agent: Wilson Sonsini Goodrich & Rosati

20070077202 - Histostain composition for endoscope: The invention relates to a histostain composition for endoscope containing one or more members selected from colors derived from Monascus. The stain composition is a staining agent which sharpens the shapes of digestive tract lumen surfaces and the like with a light in the visible wavelength range, having a function... Agent: Greenblum & Bernstein, P.L.C

20070077200 - Method and system for controlled maintenance of hypoxia for therapeutic or diagnostic purposes: Embodiments of the present invention relate to a system, device, and method for automatically inducing, maintaining, or controlling hypoxia in a patient. Specifically, embodiments of the present invention relate to delivering a hypoxic gas mixture to a patient, monitoring at least one physiological parameter of the patient, and automatically controlling... Agent: Fletcher Yoder (tyco International, Ltd.)

20070077201 - Stem cell expansion and uses: The invention relates to methods to manipulate stem cells in vivo and in vitro to treat, e.g., a conditions where cell or tissue repiar is needed.... Agent: Hollis-eden Pharmaceuticals, Inc.

20070077204 - Olfactory identification tests for cognitive diseases and disorders: The present invention provides smell tests (odor identification tests) that are shorter that UPSIT, yet has a statistical sensitivity and specificity equivalent to or better than UPSIT. The odor identification tests of the invention are based on a core set of six odorants, where the six odorants can be selected... Agent: Wilmerhale/columbia University

20070077203 - Surrogate markers: The invention provides a method to analyze an effect of a biological insult such as exposure to ionizing radiation comprising (a) exposing one or more groups of subjects to a biological insult of at least about an LD10 to obtain one or more groups of exposed subjects; and (b) measuring... Agent: Hollis-eden Pharmaceuticals, Inc.

20070077205 - Use of non-invasive imaging technologies to monitor in vivo gene-expression: The present invention provides methods of using non-invasive imaging technologies to monitor the effects of potential therapeutic compounds on gene expression in non-human living animals. This invention also provides methods to analyze perturbation in biochemical pathways and physiological functions associated with disease (e.g., a cancer, cardiovascular disease, degenerative nervous system... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070077206 - Characterization of microbial deposition and immune response at the basement membrane and methods relating thereto: Methods for diagnosing a systemic or autoimmune disorder and methods for treating the same by inducing the production of or otherwise providing an autoantibody that recognizes a skin basement membrane component.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070077207 - Method for the production of propellant gas-free aerosols from aqueous medicament preparations: The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070077208 - Pharmaceutical foam: The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized contained comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In... Agent: Townsend And Townsend And Crew, LLP

20070077209 - Stabilized particle dispersions containing nanoparticles: In one aspect, the invention provides a stable dispersion comprising a continuous phase comprising a continuous liquid phase and a plurality of organic nanoparticles; and a dispersed phase comprising particles dispersed in the continuous phase.... Agent: 3m Innovative Properties Company

20070077210 - Chewing gum and confectionery compositions containing a stain removing complex, and methods of making and using the same: A composition in the form of a chewing gum composition or a confectionery composition containing a stain removing complex of a stain removing agent and a cyclodextrin compound and methods of preparing and using the same to remove stains from dental material including teeth.... Agent: Watov & Kipnes, P.C.

20070077211 - Composition for moistening oral cavity: A composition for moistening an oral cavity is provided that has a small effusion amount of moisture contained in the composition, is hard to absorb moisture on an oral mucosa, and capable of continuously supplying moisture stably to an oral mucosa surface, the composition for moistening an oral cavity containing... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070077212 - Protein with activity of hydrolyzing amylopectin, starch, glycogen and amylose, gene encoding the same, cell expressing the same, and production method thereof: Disclosed are an enzyme, having the amino acid sequence of SEQ. ID. No. 1 with the activity of hydrolyzing amylopectin, starch, glycogen and amylose, a gene encoding the enzyme, and a transformed cell expressing the gene. Also disclosed is a method of producing an enzyme capable of degrading amylopectin, starch,... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070077213 - Accelerated method and instrumentation for whitening teeth: The invention provides a composition whitening teeth, using a bleaching compound and a catalytic activator, where the catalytic activator catalyzes the reaction of a significant portion of the bleaching compound within in a short period of time. A method for whitening teeth by providing a bleaching compound, providing a catalytic... Agent: Klarquist Sparkman, LLP

20070077215 - Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whi: e

20070077214 - Compositions comprising a uv-absorbing chromophore: wherein X1 and X2 are the same or different, and at least one of X1 or X2 is a functional group that bonds with the compound comprising at least one UV-absorbing chromophore, and b+f≧2, Y comprises an 0, N, or S that is substituted or unsubstituted, each a, b, c,... Agent: Conley Rose, P.C.

20070077216 - Fluorescent cosmetic composition: The present invention relates to a cosmetic composition containing, in a physiologically acceptable medium, fluorescent particles comprising molecules of at least one fluorescent organic compound trapped inside a matrix at least partially formed by at least one metal oxide, said composition comprising less than 100 mg/l of said fluorescent organic... Agent: Oliff & Berridge, PLC

20070077218 - Composition containing a coloring agent: The present invention relates to a composition preferably useful as a cosmetic eyeshadow containing a particular liquid fatty phase. The invention composition is characterized by its sheen. The invention also relates to a process for making up the eyelids using the composition.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070077217 - Cosmetic compositions having increased color intensity and method for producing same: (ii) an unsaturated dimerized or trimerized C14-C24 fatty acid, preferably an unsaturated dimerized or trimerized C16-C20 fatty acid that has 2 to 4, preferably 2, unsaturated bonds. Diisostearyl dilinoleate is preferred. Triisostearyl trilinoleate is most preferred. When then composition is an oil-in-water emulsion, the triisostearyl trilinoleate or diisostearyl dilinoleate is... Agent: Avon Products, Inc.

20070077220 - Stable ascorbic acid compositions: Compositions include vitamin C, water and a reducing sugar, result in increased stability of vitamin C. Further the addition of alcohol to aqueous vitamin C compositions increased the stability of vitamin C. Moreover, aqueous vitamin C compositions having surfactant included therein enhance the absorption of vitamin C into skin. Methods... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070077219 - Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy: Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.... Agent: Lathrop & Clark LLP

20070077221 - Cosmetic composition comprising an ampholytic copolymer and another agent: The present invention relates to a cosmetic composition comprising an ampholytic copolymer and another agent. The amphiphilic polymer comprises particular cationic units and anionic or potentially anionic units. The composition according to the invention satisfies consumer needs for novel compositions.... Agent: Jean-louis Seugnet Rhodia Inc.-legal Department

20070077222 - Composition and treatment for hair loss: A topical hair treatment or a topical dermatological or cosmetic composition includes a liquid having approximately 0.2 to 0.5 mg/mL of a xanthene derivative. The xanthene derivative can be a methylxanthene. The methylxanthene can be theophylline, caffeine, and/or theobromine. Preferably, the methylxanthene is caffeine selected from hydrous caffeine, caffeine salts,... Agent: Mark Young, P.A.

20070077223 - Headwear with deodorizatnt function: A headwear with specific functions, including anti-bacteria, odor proofed, deodorant, warm-keeping, and so on, comprises a sweat band made by the fabric material, wherein at least one functional fiber is within a proper section of the sweat band, such as bamboo charcoal based fiber with deodorant anti-bacterial functions, or added... Agent: Tung Hua, Tai

20070077224 - Regulation of t cell-mediated immunity by tryptophan: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in... Agent: Mueting, Raasch & Gebhardt, P.A.

20070077225 - Continuous delivery methods for treating hepatitis virus infection: The present invention provides methods of treating hepatitis virus infection. The methods generally involve administering an IFN-α by continuous delivery. Continuous delivery of IFN-α provides for a serum profile of IFN-α such that a sustained viral response is achieved.... Agent: Thelen Reid Brown Raysman & Steiner LLP

20070077232 - Conditioned cell culture medium compositions and methods of use: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal... Agent: Wilson Sonsini Goodrich & Rosati

20070077226 - Gutless adenovirus vector and the construction method thereof: The present invention disclosed a kind of gutless adenovirus vector and the construction method thereof. Two structural independent but functional related cassettes, the trans-activator (TA) and anti-tumor cassette, are both carried by the gutless vector. hTERT promoter restricts the expression of TA only in tumor cells, and RU486, associated with... Agent: Perkins Coie LLP

20070077231 - Immune effector cells pre-infected with oncolytic virus: Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect... Agent: Bozicevic, Field & Francis LLP

20070077233 - Inhibition of pathological angiogenesis in vivo: The present invention is directed to the inhibition of pathological angiogenesis in different tissues such as cancer, tumor, retinal or synovial tissue. It has been shown that over expression of RB2/p130 modulates the angiogenetic balance. It has been further shown that induction of RB2/p130 expression using a tetracycline-regulated gene expression... Agent: Reed Smith LLP

20070077230 - Method for the pre-conditioning/fixation and treatment of diseases with heat activation/release with thermo-activated drugs and gene products: A method of treating cancer by introducing heat into cancerous tissue and delivering a liposome containing an active agent or a thermo-activated drug, gene or virus to said tissue. The heat delivered is sufficient to release the active agent or activate the thermo-activated drug, gene or virus. The cancer can... Agent: Venable LLP

20070077228 - Method of treating or retarding the development of blindness: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the... Agent: Howson And Howson

20070077227 - Nucleic acid binding proteins: The invention provides a method for designing a nucleic acid binding protein of the Cys2-His2 zinc finger class capable of binding to a nucleic acid quadruplet in a target nucleic acid sequence, wherein binding to base 4 of the quadruplet by an alpha-helical zinc finger nucleic acid binding motif in... Agent: Townsend And Townsend And Crew, LLP

20070077229 - Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin: A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a KLH1 haemocyanin, a haemocyanin domain or a fragment thereof with the immunological properties of at least one domain of haemocyanin, and comprises at least one intron sequence, as well... Agent: Welsh & Katz, Ltd

20070077234 - Regulation of t cell-mediated immunity by tryptophan: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in... Agent: Mueting, Raasch & Gebhardt, P.A.

20070077238 - Production of organic and inorganic selenium compounds by lactic acid bacteria: A novel strain of lactic acid bacteria was found to be heat resistant and able to grow in a sulfur-limiting medium (SLM) containing a high concentration of sodium selenite. The microorganism is a non-spore forming and Gram-positive coccus, which is identified with >90% confidence using the API biochemical and sugar... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. The Financial Center

20070077235 - Composition and method of treating mastitis: A composition and method for treating bacterial infections by the use of an effective amount of at least one lytic specific for the bacteria causing specific. The lytic enzyme is genetically coded for by a bacteriophage which may be specific for said bacteria. The enzyme may be at least one... Agent: Jonathan Edwin Grant

20070077236 - Method for cell implantation: An endoscopic method for treating cartilage or bone defects in an animal, said method comprising the steps of: I) identifying the position of the defect, ii) applying cells selected from the group consisting of chondrocytes, chondroblasts, osteocytes and osteoblasts and combinations thereof into the cartilage or bone defect. In particular,... Agent: Edwards & Angell, LLP

20070077237 - Method for freezing, thawing and transplantation of viable cartilage: Disclosed is a method for providing a patient having impaired cartilage in an organ at a target site, with corresponding viable cartilage, possibly osteochondral cartilage. The method comprises freezing the cartilage by cooling it at a cooling rate of 0.01° C./min to 3° C./min. Thawing of the cartilage may be... Agent: Nath & Associates

20070077239 - Peptide carrier for drug delivery: The present invention is directed to compositions based on myeloperoxidase amino acid sequence which may be used as therapeutic agents or as delivery vehicles for the delivery of other therapeutic agents.... Agent: Marshall, Gerstein & Borun LLP

20070077241 - Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives: The present invention provides various methods for stimulating a cell expressing an NKG2D receptor, including artificially engineered cell populations. Provided, in accordance with the invention, are monoclonal antibodies that bind to NKG2D extracellular domains and facilitate the interaction of other NKG2D domains with DAP10. Of particular interest are treating cancers... Agent: Fulbright & Jaworski L.L.P.

20070077242 - Anti-cd40 monoclonal antibody: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070077240 - Immunoglobulins devoid of light chains: The invention relates to an immunoglobulin having determined antigen specificity, and having a variable fragment which is derived from a so-called heavy-chain immunoglobulin having two heavy polypeptide chains capable of recognizing and binding one or several antigens and which is further naturally devoid of light chains, wherein the immunoglobulin having... Agent: Wolf Greenfield & Sacks, PC

20070077243 - Method for making humanized antibodies: Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.... Agent: Genentech, Inc.

20070077244 - Inhibitor protein of the wnt signal pathway: The present invention relates to an inhibitor protein of the wnt signal path, a DNA encoding such a protein and a process for the preparation of such a protein. In addition, this invention concerns the use of the DNA and the protein as well as antibodies directed against the protein.... Agent: Howrey LLP

20070077246 - Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity: The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such... Agent: Jones Day

20070077245 - Notch mutations leading to increased receptor signaling: The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increased receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for... Agent: Law Office Of Michael A. Sanzo, LLC

20070077247 - Receptor on the surface of activated t-cells: act-4: The invention provides purified ACT-4 receptor polypeptides, antibodies against these polypeptides and nucleic acids encoding ACT-4 receptor polypeptides. Also provided are methods of diagnosis and treatment using the same. ACT-4 receptors are preferentially expressed on the surface of activated CD4+ T-cells. ACT-4 receptors are usually expressed at low levels on... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070077249 - Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the... Agent: Wolf Greenfield & Sacks, PC

20070077248 - Tumour necrosis factor binding ligands: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of... Agent: Morrison & Foerster LLP

20070077251 - Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds.... Agent: Licata & Tyrrell P.C.

20070077250 - Novel core 2 beta-1,6-n-acetylglycosaminyltransferase gene: The invention provides novel core 2 β-1,6-N-acetylglycosaminyltransferase nucleic acids, and polypeptides encoded by the nucleic acids. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists, and methods for treating disorders associated with the enzyme.... Agent: Millen, White, Zelano & Branigan, P.C.

20070077252 - Laminin chains: diagnostic uses: The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070077253 - Immunogenic compositions and methods of use: Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic... Agent: Cantor Colburn, LLP

20070077255 - Isolation and characterization of a cdna clone encoding one ige-binding fragment of penicillium brevicompactum: Pen b 26 was isolated as an allergen of Penicillium brevicompactum, which is known to be one of the major source of indoor fungal allergies. Pen b 26 was isolated and cloned into Escherichia coli as an N-terminus his-tagged fusion protein, which had a calculated molecular weight of 14.9 kDa... Agent: Ade & Company Inc.

20070077254 - Targeting the histone code as a bacterial strategy for selectively modulating gene expression: The ospF gene of Shigella flexneri encodes a phosphatase, which is a member of a new class of phosphatases. The OspF phosphatase inhibits the activity of several proteins either by direct protein modification or transcription downregulation. These proteins include MAP kinase, IL-8, CCL20, IL-12, AP1, CREB, RPA p32, and BCL2... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070077256 - Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic... Agent: Mcdermott, Will & Emery

20070077257 - Enhanced first generation adenovirus vaccines expressing condon optimized hiv1-gag, pol, nef and modifications: First generation adenoviral vectors and-recombinant adenovirus-based HIV vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof are described. The adenovirus vaccines, when directly introduced into living vertebrate tissue, express the relevant proteins, inducing a cellular immune response which specifically recognizes HIV-1.... Agent: Merck And Co., Inc

20070077258 - Administration of glutathione (reduced) via intravenous or encapsulated in liposome for the amelioration of tnf-alpha effects and flu-like viral symptoms and treatment and prevention of virus: The invention is a method of treatment of the symptoms related to inflammation that accompanies the release of Tumor Necrosis Factor-alpha in diseases such as viral infection such as those affecting the respiratory tract by providing systemic glutathione (reduced) by oral administration of glutathione (reduced) in a liposome encapsulation or... Agent: Brooke Schumm Iii

20070077259 - Compositions and methods for topical application and transdermal delivery of botulinum toxins: Improved formulations for transdermal delivery of botulinum toxin are disclosed. The formulations include, for example, botulinum toxin non-covalently associated with a positively charged backbone having branching or efficiency groups. The formulations also include a partitioning agent, oligo-bridge, or polyanion bridge, and may optionally contain a viscosity modifying agent. The formulations... Agent: Morgan & Finnegan, L.L.P.

20070077260 - Vaccines for mycoplasma bovis and methods of use: The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of... Agent: Kenyon & Kenyon LLP

20070077261 - Compositions and method for enhancing the solubility of ascorbic acid using solubilization enhancers: A method for dissolving ascorbic acid in a nonaqueous alcohol solvent using a solubilization enhancer is described. The amount of ascorbic acid solubilized in the nonaqueous alcohol solvent containing the solubilization enhancer is greater than the amount of ascorbic acid that would be soluble in the nonaqueous alcohol solvent without... Agent: Jerry Zhang

20070077262 - Puleganic acid insect repellents: The present invention relates to compositions of puleganic acid, and the use thereof as a topical treatment for skin, such as a repellant for insects or arthropods.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070077263 - Puleganic amides: The present invention provides substituted puleganic amides and compositions thereof, which are both useful as a topical treatment for skin, such as a repellant for insects and arthropods.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070077264 - Packaging for chemical moth and insect repellent products: A packaging system for repeatably storing chemical moth and insect repellent products that hinders oxygen and ultraviolet lighting from penetrating to prevent sublimation of the product prior to purchase. A user can store unused products after initial use and reopen the package at a later time to minimize the unused... Agent: Paul D. Bianco: Fleit, Kain, Gibbons, Gutman, Bongini, & Bianco P.l.

20070077265 - Article tissue systems and uses thereof: An implant system and a method for controlling the natural and artificial microenvironments surrounding an implanted device using an artificial tissue system (ATS) and includes methods of diagnostic and testing related thereto. The ATS, among other things, induce better integration, function, and extended lifespan of the devices at the site... Agent: Alix Yale & Ristas LLP

20070077267 - Bioactive composite implants: A composite spinal implant device including collagen and/or synthetic fibers impregnated with a bioactive formulation is disclosed. Also disclosed are methods of making the composite spinal implant devices, surgeries using the device, and kits containing the device.... Agent: Hunton & Williams LLP Intellectual Property Department

20070077270 - Delivery devices and methods for long-term, targeted delivery of therapeutic agents to the eye and ear: Disclosed are devices and methods for targeted delivery of therapeutic agents. The devices include selectively permeable hollow fiber membranes which allow for the outward diffusion of therapeutic agents while the contents of the device are protected from host humoral and cellular immunologic attack. The methods include implanting the devices in... Agent: Dority & Manning, P.A.

20070077266 - Drug/gene eluting stent: The present invention provides a more safe and highly effective stent having functions such as anti-inflammatory action, antithrombotic action, maintenance of tissue restoration response and maintenance of endothelial regeneration. More specifically, the drug/gene eluting stent has a layer containing a gene encoding a hybrid polypeptide on the surface. The hybrid... Agent: Nixon & Vanderhye, PC

20070077268 - Hydrophobic carrier modified implants for beneficial agent delivery: Disclosed is a bearing material for a medical implant or medical implant part, the bearing material comprising: (a) a matrix of crosslinked polyethylene, (b) a biocompatible hydrophobic carrier, and (c) a beneficial agent soluble in the biocompatible hydrophobic carrier. Also disclosed are methods for preparing a bearing material in accordance... Agent: Leydig Voit & Mayer, Ltd

20070077271 - Medical devices coated with a fast dissolving biocompatible coating: The present invention relates to a medical device comprising a biocompatible medical coating adhered thereto, wherein the coating comprises at least one of a non-crosslinked, water soluble salt of: (i) alginic acid, (ii) hyaluronic acid or (iii) chitosan, wherein the coating is readily dissolvable in at least one mammalian body... Agent: Patent Administrator Fmc Corporation

20070077274 - Method for producing shaped bodies based on crosslinked gelatine: A method for producing shaped bodies based on crosslinked gelatin, which may be used as carrier material for tissue implants and have an individually adjustable degradation time, is disclosed, comrising: a) preparing an aqueous gelatin solution; b) partially crosslinking the dissolved gelatin; c) producing a shaped body starting off from... Agent: Leydig Voit & Mayer, Ltd

20070077269 - Method of birth control and hormone regulation: A method of birth control and hormone regulation comprises utilizing a vaginal ring worn continuously during each menstrual cycle. A vaginal ring delivers predetermined doses of progesterone and beta-estradiol. Beta-estradiol does not cause an increase in sex hormone binding globulin and thereby does not decrease a woman's levels of free... Agent: Michael A. O'neil Michael A. O'neil, P.C.

20070077273 - Microfabricated nanopore device for sustained release of therapeutic agent: A drug delivery device that includes a capsule for implantation into the body; the capsule further includes a reservoir for containing a substance such as a therapeutic agent, at least one port for allowing the substance to diffuse from or otherwise exit the reservoir, and a nanopore membrane in communication... Agent: Mcnees, Wallace & Nurick LLC

20070077275 - Multilayer films, coatings, and microcapsules comprising polypeptides: Disclosed herein are multilayer films comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polypeptide comprising one or more first amino acid sequence motifs, wherein the one or more first amino acid sequence motifs has a length of 5 to 15 amino... Agent: Cantor Colburn, LLP

20070077276 - Multilayer films, coatings, and microcapsules comprising polypeptides: Disclosed herein is a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolye comprises a composite polypeptide comprising one or more surface adsorption regions covalently linked to one or more functional regions forming a single polypeptide chain. The surface... Agent: Cantor Colburn, LLP

20070077272 - Solid polymer delivery compositions and methods for use thereof: The present invention provides an implantable solid polymer delivery composition that can be formulated to release a bioactive agent to an interior body site at a controlled rate over an extended period of time by adjusting the various components of the composition. The controlled delivery of the composition avoids an... Agent: Dla Piper US LLP

20070077277 - Compositions and uses thereof: Methods of controlling serum glucose levels in an individual are described, the methods including the step of administering to said individual a therapeutic food composition comprising a waxy and/or hydrothermally treated starch. The method may be used to treat or prevent hypoglycaemia in patients susceptible to hypoglycaemic episodes, for example... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070077278 - Polysaccharide-containing composition and tear film stabilizing ophthalmic solution: An object of the present invention is to provide a composition which is excellent in safety and capable of dispersing uniformly on the mucous tissue when topically administered to mammals, and an ophthalmic solution comprising the composition and capable of stabilizing the tear film and keeping the tear film on... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070077279 - Novel compositions containing polyphenols: The present invention is directed to compositions containing at least a polyphenol and polyethylenglycol, to products such as food, beverages, dietary supplements, feed, pharmaceuticals and personal care products containing such a composition as well as to the use of polyethylenglycol for masking the bitter taste of such polyphenols. The polyphenols... Agent: Nixon & Vanderhye, PC

20070077280 - Wound treatment medium and method of packaging and use: A sterile wound treatment kit includes a plastic container pouch with a sealed outer periphery which forms a sterile interior region which isolates the pouch interior from a surrounding environment. A drug absorbing medium is located within the pouch interior and initially isolated from the surrounding environment by the sealed... Agent: Whitaker, Chalk, Swindle & Sawyer, LLP

20070077282 - Adhesive patch for external use on skin: A pressure-sensitive adhesive composition which comprises three ingredients, i.e., polyisoprene, a styrene/isoprene/styrene copolymer, and solid polyisobutylene, in a proportion of (10-60)/(10-50)/(20-60) by weight and further contains a non-solid isobutylene polymer and a tackifier, characterized in that the amount of the non-solid isobutylene polymer is 1 to 30 pts. wt., excluding... Agent: Licata & Tyrrell P.C.

20070077281 - Medical skin patches with a content of essential oils for treating colds, and processes for their production: Medical skin patches for treating colds by releasing essential oils through evaporation comprising a backing layer permeable to gas and water vapour and a hydrophile and pressure-sensitive adhesive polymer matrix connected to the backing layer. The matrix contains at least one essential oil, at least one hydrophile polymer, at least... Agent: D. Peter Hochberg Co. L.p.a.

20070077283 - Method of enhancing transmucosal delivery of therapeutic compounds: A composition comprising a biologically active agent and a permeation enhancing lipid wherein the permeation enhancing lipid is a platelet activating factor antagonist or a biologically inactive a platelet activating factor, and increases permeability of the biologically active agent across a tissue layer. Also disclosed is a process of increasing... Agent: Nastech Pharmaceutical Company Inc

20070077285 - Adhesive skin patch: The present invention provides an adhesive skin patch that permits excellent and prolonged percutaneous absorption of tulobuterol and that can be stably applied to the skin for a long period of time with less skin irritation. The adhesive skin patch comprises a base material and a medicated layer provided on... Agent: Sughrue Mion, PLLC

20070077286 - Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle: To provide an external preparation or injectable preparation that exerts the effect of enabling transdermal or transmucosal in viva absorption of fat-soluble drugs and water-soluble drugs not having been satisfactorily attained hitherto and that contains a highly absorbable fat-soluble/water-soluble drug, the injectable preparation especially aiming at sustained-release and target effects.... Agent: Ostrager Chong Flaherty & Broitman PC

20070077287 - Transdermal art patch: A transdermal patch having a pre-selected amount of a predetermined absorbable medicine thereon for attaching to an individual's skin. The transdermal patch includes a backing member having a predetermined size and a predetermined shape. The backing member has a first surface and a radially opposed second surface. A medicinal adhesive... Agent: James Ray & Associates

20070077288 - Transdermal delivery of non-steroidal anti-inflammatory drugs: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a non-steroidal anti-inflammatory drug; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least... Agent: Foley And Lardner LLP Suite 500

20070077284 - Transdermal formulation comprising an opioid analgesic and an aloe composition: The invention concerns a formulation comprising an apioid analgesic from the phenanthrene group or a pharmaceutically acceptable salt thereof as active ingredient and an aloe composition as transdermal penetration agent.... Agent: Ronald R Santucci Frommer Lawrence & Haug

20070077292 - Compositions and methods for improved skin care: Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070077289 - Cream containing interferon encapsulated with liposome: This invention relates to a cream containing interferon encapsulated with liposome, which comprises IFN liposome and cream substrate. The advantage of the cream of the present invention is high efficiency of encapsulation, stable production technique, good homogeneity of products, stable efficacy and low rate of leakage. In order to improve... Agent: Workman Nydegger (f/k/a Workman Nydegger & Seeley)

20070077291 - Drug delivery nanocarriers targeted by landscape phage: A targeted drug delivery nanocarrier and a method of forming the same is disclosed herein. The targeted drug delivery nanocarrier includes a plurality of amphipathic molecules forming a carrier particle having a plurality of drug molecules contained therein. A targeted landscape phage protein assembly is complexed to the carrier particle... Agent: Andrus, Sceales, Starke & Sawall, LLP

20070077290 - High delivery rates for lipid based drug formulations, and methods of treatment thereof: Provided is a method of preparing lipid based drug formulations with low lipid/drug ratios using coacervation techniques. Also provided are methods of delivering such lipid based drug formulations at high delivery rates, and methods of treating patients with pulmonary diseases comprising administering such lipid based drug formulations.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070077294 - Capsules comprising topiramate: Pharmaceutical capsules containing uncoated particles comprising topiramate and an acid-insoluble polymer.... Agent: Nixon & Vanderhye, PC

20070077293 - Film-forming composition suitable for hard capsules and method for preparing the same: The present invention relates to a film-forming composition suitable for hard capsules, and a preparation method thereof. More particularly, the invention relates to a film-forming composition for hard capsules, comprising 7-12% by weight of starch, 1-6% by weight of a plasticizer, 0.7-3% by weight of a gelling agent, and 79-91.3%... Agent: Buchanan, Ingersoll & Rooney PC

20070077295 - Method and composition for pharmaceutical product: This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF.... Agent: Intellectual Property Department Gilead Sciences, Inc.

20070077297 - Modified release ibuprofen dosage form: The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8... Agent: Ratnerprestia

20070077296 - Pharmaceutical preparation containing meloxicam: The invention relates to novel solid formulations comprising as pharmaceutically active compound meloxicam and to processes for producing such solid formulations. The invention furthermore relates to a method for manufacturing a medicament for the prevention and/or treatment of pain, inflammation, fever, acute mastitis, diarrhoea, locomotive disorders, lameness, osteoarthritis, problems of... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070077298 - Soy-based thermosensitive hydrogels for controlled release systems: Biopolymeric hydrogel precursors are prepared by means of a ring-opening polymerization of epoxidized vegetable oils, followed by chemical hydrolysis. The recovered hydrogels having properties similar to Pluronic® type surfactants would have a plurality of end-use applications, including use as food additives and pharmaceutical ingredients. This invention provides the potential for... Agent: Usda-ars-office Of Technology Transfer National Ctr For Agricultural Utilization Research

20070077300 - Oral compositions containing a salivation inducing agent: Oral dosage forms, and particles used therein, containing salivation inducing agents are disclosed. The salivation agents may be in the core of the dosage form and/or in coatings applied thereto, or alternatively may be within particles and/or the matrix of such dosage forms, in coatings applied to such particles, or... Agent: Philip S. Johnson Johnson & Johnson

20070077299 - Oral formulation for 5-ht-receptor agonists, uses and methods of treatment employing the same: A pharmaceutically acceptable oral formulation comprising core material which comprises a therapeutically effective amount of a 5-HT-receptor agonist, or a pharmaceutically acceptable salt, solvate or derivative thereof, which core material is provided with a substantially water resistant coating comprising one or more substantially water resistant materials.... Agent: Conley Rose, P.C.

20070077301 - Venlafaxine osmotic device formulation: The present invention provides an osmotic device containing controlled release venlafaxine in the core, wherein the osmotic device exhibits a reduced food effect as compared to a reference controlled release capsule formulation. Some embodiments include venlafaxine in controlled release form in combination with an anti-Alzheimer's or an anti-Parkinson's drug in... Agent: Innovar, LLC

20070077303 - Methods for providing oxidatively stable ophthalmic compositions: This invention relates to a process for improving the stability of an ophthalmically compatible solution comprising at least one oxidatively unstable ophthalmic compound.... Agent: Philip S. Johnson Johnson & Johnson

20070077302 - Methods for stabilizing ophthalmic compositions: The present invention relates to a method comprising stabilizing, during autoclaving, an oxidatively unstable ophthalmic compound dissolved in an ophthalmic solution by incorporating a stabilizing effective amount of at least one electron rich polymer in said ophthalmic solution.... Agent: Philip S. Johnson Johnson & Johnson

20070077304 - Sustained release small molecule drug formulation: An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having Cmax to Cmin ratio less than 200 and... Agent: Dewipat Incorporated

20070077305 - Biocompatible polymeric matrix and preparation thereof: The invention discloses a biocompatible polymeric matrix which is functionalized through the reaction with a functionalizing agent including protonated carboxylic acid groups. There is also disclosed a method of preparation of the polymeric matrix and a pharmaceutical composition including the matrix as a carrier for controlled release of a bioactive... Agent: Ogilvy Renault LLP

20070077306 - Apatite particle, method of producing the same, apatite particle-gene complex, and method of gene transfection: When a solution of an inorganic phosphoric acid, added to with calcium ions and magnesium ions, is incubated for a preset time duration, an apatite particle obtained is reduced in size, depending on the concentration of the magnesium ions. By employing an apatite particle, for which the concentration of the... Agent: Patterson & Sheridan L.L.P.

20070077307 - Pharmaceutical compositions: The present invention relates to a pharmaceutical composition comprising primarily amorphous 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester.... Agent: Robert Deberardine Abbott Laboratories

20070077309 - Banded controlled release nanoparticle active agent formulation dosage forms and methods: Disclosed are controlled release dosage forms and related methods wherein controlled release of self-dispersing nanoparticle active agent formulations is provided by formulating porous particles into which have been sorbed a self-dispersing nanoparticle active agent formulation.... Agent: Philip S. Johnson Johnson & Johnson

20070077308 - Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients: The present invention relates to microcapsules and a continuous micro-encapsulation water-in-oil-in-water microencapsulation process through in situ and interfacial polymerisation of the emulsion. The formulation comprises a continuous water phase having a dispersion of microcapsules which contain oil drops and wherein the inside of each oil phase drop—containing optionally oil-soluble materials—there... Agent: Vedder Price Kaufman & Kammholz

20070077310 - Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species: The subject application provides methods of identifying compounds, combinations of compounds, compositions, and/or combinations of compositions that are suitable for reducing the production of reactive oxygen species (ROS) in an individual with the proviso that said compound, combination of compounds, composition, or combination of compositions is not a dietary material... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070077311 - Fumigant/sterilant: A fumigant/sterilant comprising an effective amount of cyanogens mixed with a predetermined amount of carbon dioxide such that, in use, the fumigant/sterilant remains below its flammability limit. A method of producing said fumigant/sterilant is also provided.... Agent: The Boc Group, Inc.

20070077312 - Silver- and zinc- containing body care agent: The invention relates to a body care agent containing metal particles which release zinc and silver ions in said body care agent by contacting body liquid or body humidity and whose metallic silver content at least equal or greater than 99% (m/m).... Agent: Leydig Voit & Mayer, Ltd

20070077313 - Toleration iron supplement compositions: The invention relates to compositions and methods for the treatment or prophylaxis of iron deficiency, and in particular of iron deficiency anemia, by administering a composition containing an effective amount of a pharmaceutically acceptable ferrous iron salt; and an effective amount of polysaccharide iron complex.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070077314 - Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis: A composition comprising a powder mixture of potassium citrate and calcium citrate as mixtures of pure chemical salts and methods of making and using the composition are disclosed. The composition is useful for the treatment and prevention of kidney stones and osteoporosis and better delivers potassium and calcium than commonly... Agent: Fulbright & Jaworski, LLP

20070077315 - Child discipline composition and method: A composition for substantially deterring unwanted behaviors in children is provided. The composition comprises water, goldenseal tincture, and apple cider vinegar in an effective amount. The composition is sprayed toward the mouth of the child after the child engages in the unwanted behavior. The composition may be sprayed from an... Agent: Weiss & Moy PC

20070077316 - Compositions and methods for treating and preventing virus infections: Provided are compositions comprising a vanilloid and tea catechins in amounts and proportions which combat virus infections in a human or animal. The vanilloid can be provided in the form of a dried pepper preparation and the tea catechins can be provided in the form of a green tea extract... Agent: Greenlee Winner And Sullivan P C

20070077317 - Olive kernel composition containing absorption promoters, antioxidants, and anti-inflammatory agents: The claimed invention is composition comprising an organic extract of de-fleshed, purified, isolated olive kernels that contains one or more components that increase absorption of macromolecules such as proteoglycans across cell membranes, that have antioxidant properties, and that have anti-inflammatory effects in tissues.... Agent: Dr. Melvin Blecher

20070077318 - Process for producing cocoa polyphenol concentrate: Process for obtaining cocoa polyphenol concentrate includes: a) subjecting unfermented cocoa beans to a blanching step in water at a temperature ranging from 85-100° C. for a period ranging from 3 to 15 minutes to give unfermented cocoa beans with reduced polyphenol oxidase activity; b) drying the unfermented cocoa beans... Agent: Young & Thompson